Join us for the President’s Reception and Banquet

Saturday, October 31, 2015
6:30 – 10 p.m.

Join us on Halloween for a haunting evening at the extraordinary Fairmont Château Frontenac!

See page 32 for details.
Welcome

DEAR FRIENDS AND COLLEAGUES:

Thank you to all Section members, industry partners and other attendees for coming to Québec City. We are privileged to welcome you to the Section’s 67th Annual Meeting and the beautiful Fairmont Le Château Frontenac. While attending our sessions, take time to enjoy spectacular views of the St. Lawrence River and be inspired by the unique charm of one of the most beautiful and walkable cities in the world.

As you read this year’s program, you will see that we have put together 18.25 hours of scientific exchange. The meeting emphasizes practical approaches for managing clinical problems. As stated in our meeting objectives, we expect the featured talks, panel discussions and debates to directly help you in your practice — to be aware of recent developments in multiple topic areas, to improve your evaluations and assessments of patients, to embrace new trends – all to equate to an excellent educational experience. All fields of urology will be discussed in a mixed fashion, in an attempt to create brilliance and encourage exchange of ideas. In addition, specific oncological topics will be discussed during the Saturday’s half-day joint program with the Quebec Urological Association. Of course, your questions and active participation in the sessions are strongly encouraged and help in making learning fun.

In addition to our scientific program, join us for social events which start on Thursday evening in the exhibit hall and Friday’s Fun Night event at the beautiful and breathtaking Parliament building. Our Fun Night entertainment will be provided by the famous Patrice Painchaud Trio, a world renowned show promoting international and Quebecoise music. And don’t forget your registration includes a third night of entertainment at Saturday’s banquet event. In addition we have arranged tour options during each day of the meeting which include fine arts, the Island of Orleans and a tour of the city’s history.

Thank you again for being here. Please say hello to us and share your ideas and questions. We look forward to each of you making this a productive and enjoyable meeting.

Joseph Greco, MD   Julie Franc-Guimond, MD
President    Scientific Program Chair
SCHEDULE-AT-A-GLANCE

THURSDAY, OCTOBER 29, 2015
• Plenary Sessions: The Intruders and Family & Friends
• Stone Extraction Challenge
• Moderated Poster Sessions
• Industry-sponsored Symposia*
• Exhibit Hall Grand Opening Reception
• Tour Option: Fine Arts Museum

FRIDAY, OCTOBER 30, 2015
• 5K Fun Run/Walk
• Plenary Sessions: The Male Factor and The Challenges
• George E. Slotkin Lecture: Trends in International Education: Implications for Northeastern Section Urologists and Trainees
• AUA Course of Choice: Contemporary Issues in Testosterone Deficiency: Diagnosis and Management
• Moderated Poster Sessions
• Stone Extraction Challenge
• Annual Business Meeting
• Tour Option: Island of Orléans
• Fun Night at Parliament

SATURDAY, OCTOBER 31, 2015
• Residents & Young Urologists Breakfast – Cultural Competency in Healthcare
• NSAUA & QUA Joint Uro-Oncology Meeting
• Tour Option: Discover Québec, A Historical City
• President’s Reception & Banquet

*Industry-sponsored symposia are separate from the Section’s designated CME scientific program.
### THURSDAY, OCTOBER 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8 a.m.| FRONTENAC         | 7:45 - 8:15 a.m. Welcome Remarks  
Plenary I: The Intruders  
Forum: Surgeon and Patient’s Safety |
| 9 a.m.|                  | 9 - 9:30 a.m. Contemporary Medical Management of Urolithiasis: A Guidelines Based Approach  
9:30 - 10 a.m. Lecture - Bugs and Surgeons: Personal Lessons from the Urinary Tract  
10 - 10:15 a.m. Resident Debate  
10:15 - 10:30 a.m. Break |
| 11 a.m.|                  | 10:30 a.m. - 12 p.m. Moderated Poster Session II  
Pediatrics/Trauma/Reconstruction/Voiding Dysfunction  
10:30 a.m. - 12 p.m. Moderated Poster Session I  
Laparoscopy/Robotics/Education |
| Noon  |                  | 12:15 p.m. Industry Lunch Symposium  
12 - 1 p.m. Industry Lunch Symposium  
12:45 - 3:30 p.m. Exhibit Hall Open |
| 1 p.m.|                  | 1:15 p.m. Exhibit Hall Sneak Peek Dessert Reception  
Stone Extraction Challenge  
1:45 - 2:15 p.m. Vesicoureteral Reflux: Current Risk Based Management  
2:15 - 2:45 p.m. Mesh Sling Complications Diagnosis & Treatment  
2:45 - 3:15 p.m. Social Media in Urology  
3:15 - 3:30 p.m. Break in Exhibit Hall |
| 2 p.m.|                  | 3:30 - 5 p.m. Moderated Poster Session III  
Oncology I  
3:30 - 5 p.m. Moderated Poster Session IV  
Stones/Endourology/BPH/Infertility/General |
| 3 p.m.|                  | 3:30 - 5 p.m. Moderated Poster Session IV  
Stones/Endourology/BPH/Infertility/General  
3:30 - 5 p.m. Moderated Poster Session III  
Oncology I |
| 5 p.m.|                  | 5 - 6 p.m. Industry Reception Symposium  
6 - 7 p.m. Exhibit Hall Reception |
| 7 p.m.|                  |                                                                                             |
## FRIDAY, OCTOBER 30

<table>
<thead>
<tr>
<th>Time</th>
<th>Frontenac</th>
<th>Montmagny</th>
<th>Beauharnois</th>
<th>Salon Rose</th>
<th>Salle de Bal/Vercheres</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6:45 - 7:45 a.m. Industry Breakfast Symposium</td>
</tr>
<tr>
<td>8 a.m.</td>
<td><strong>Plenary III: The Male Factor</strong>&lt;br&gt;8 - 8:30 a.m. Reoperation for Male Stress Urinary Incontinence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 - 9 a.m. Prostate Cancer: Not Every Male is Managed the Same</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 a.m.</td>
<td>9 - 9:30 a.m. BPH: Trends and Recommendations</td>
<td>9:30 - 10 a.m.</td>
<td>Break in Exhibit Hall</td>
<td>9:30 a.m. - 1:30 p.m.</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td>10 a.m.</td>
<td>Break in Exhibit Hall</td>
<td>10 - 11 a.m.</td>
<td>AUA Course of Choice&lt;br&gt;Contemporary Issues in Testosterone Deficiency: Diagnosis and Management</td>
<td>9:30 a.m. - 1:30 p.m.</td>
<td>Exhibit Hall Open</td>
</tr>
<tr>
<td>11 a.m.</td>
<td>11 a.m. - 12:30 p.m. Moderated Poster Session V&lt;br&gt;Oncology 2</td>
<td>11 a.m. - 12:30 p.m.</td>
<td>Moderated Poster Session VI&lt;br&gt;Basic Science</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noon</td>
<td>12:30 - 1:30 p.m. Lunch in Exhibit Hall &amp; Stone Extraction Challenge</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 p.m.</td>
<td>Plenary IV: The Challenges&lt;br&gt;1:15 - 1:45 p.m. George E. Slotkin Lecture&lt;br&gt;Trends in International Education: Implications for Northeastern Section Urologists and Trainees</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 p.m.</td>
<td>1:45 - 3 p.m. Forum: Pain, Physical Disabilities, Technical Difficulties &amp; Surgical Failures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 p.m.</td>
<td>3 - 3:15 p.m. - Break</td>
<td>3:15 - 3:45 p.m.</td>
<td>AUA Guidelines Update</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 p.m.</td>
<td>3:45 - 4:45 p.m. Section Stars Session&lt;br&gt;Prize Essay Winners, Best Posters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 p.m.</td>
<td>4:45 - 5:30 p.m. NSAUA Annual Business Meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Frontenac

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 a.m.</td>
<td>Residents &amp; Young Urologists Breakfast</td>
</tr>
<tr>
<td>8 a.m.</td>
<td><strong>Plenary V: The Enemy - Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>8:05 - 8:15 a.m.  Best of Oncology Posters</td>
</tr>
<tr>
<td></td>
<td>8:15 - 8:30 a.m.  Hormone Therapy in Prostate Cancer</td>
</tr>
<tr>
<td></td>
<td>8:15 - 8:40 a.m.  Hormone Ablation in Advanced Prostate Cancer: When &amp; How</td>
</tr>
<tr>
<td></td>
<td>8:40 - 9:05 a.m.  Cardiovascular Disease &amp; Androgen Deprivation Therapy - Perspectives of a Cardiologist and Epidemiologist</td>
</tr>
<tr>
<td></td>
<td>9:05 - 9:30 a.m.  Management of CRPC in 2015 and Beyond</td>
</tr>
<tr>
<td>9 a.m.</td>
<td>9:30 - 9:45 a.m.  Resident Debate</td>
</tr>
<tr>
<td>10 a.m.</td>
<td>9:45 - 10 a.m.  Break</td>
</tr>
<tr>
<td>10 a.m.</td>
<td>10 - 10:30 a.m.  Current Status, Paradigms and Advances in Trimodality Bladder-Sparing Therapy for Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>11 a.m.</td>
<td>10:30 - 11:50 a.m.  Potpourri Educational Forum: Controversies in Urologic Cancers</td>
</tr>
<tr>
<td>11 a.m.</td>
<td>10:30 - 10:50 a.m.  Therapeutic Role of Lymphadenectomy in Upper Tract Urothelial Carcinoma</td>
</tr>
<tr>
<td></td>
<td>10:50 - 11:10 a.m.  Should All Patients with a Small Renal Mass Undergo a Biopsy?</td>
</tr>
<tr>
<td></td>
<td>11:10 - 11:30 a.m.  Management of Persistent Positive Cytology</td>
</tr>
<tr>
<td></td>
<td>11:30 - 11:50 a.m.  Do Patients with Elevated PSA Require Other Ancillary Tests Prior to Prostate Biopsy?</td>
</tr>
<tr>
<td>Noon</td>
<td>11:50 a.m. - Noon  Closing Remarks</td>
</tr>
</tbody>
</table>

### Salon Rose

- **6 p.m.**
  - President’s Reception & Banquet

**Saturday’s scientific program will be a joint Uro-Oncology meeting of the Northeastern Section, AUA and the Québec Urological Association.**

Earn up to 3.5 CME credits for Saturday’s joint oncology meeting.
2014 – 2015 BOARD AND COMMITTEES

NORTHEASTERN SECTION BOARD OF DIRECTORS

**PRESIDENT**
Joseph M. Greco, MD  
*Buffalo, New York*

**PRESIDENT-ELECT**
Ronald P. Kaufman Jr., MD  
*Albany, New York*

**IMMEDIATE PAST PRESIDENT**
Jerzy B. Gajewski, MD  
*Halifax, Nova Scotia*

**SECRETARY**
Timothy D. Averch, MD  
*Pittsburgh, Pennsylvania*

**TREASURER**
D. Robert Siemens, MD  
*Kingston, Ontario*

**TREASURER-ELECT**
Kenneth T. Pace, MD  
*Toronto, Ontario*

**HISTORIAN**
Ronald Rabinowitz, MD  
*Rochester, New York*

**AUA BOARD REPRESENTATIVE**
John Denstedt, MD  
*London, Ontario*

**REPRESENTATIVES**

**Canada**
Alp Sener, MD  
*London, Ontario*

**New York**
Elise J. Billings De, MD  
*Albany, New York*

**Pennsylvania**
Jodi Maranchie, MD  
*Pittsburgh, Pennsylvania*

**At-Large Canada**
Julie Franc-Guimond, MD  
*Montréal, Québec*

**At-Large United States**
Gennady Bratslavsky, MD  
*Syracuse, New York*

**YOUNG UROLOGIST MEMBERS**
Darren Beiko, MD  
*Kingston, Ontario*

Oleg Shapiro, MD  
*Syracuse, New York*

**EXECUTIVE DIRECTOR**
Drew N. Shifflet, CAE

2014 – 2015 COMMITTEES

**BYLAWS COMMITTEE**
Timothy Averch, MD, Chair  
Jean Joseph, MD  
Alp Sener, MD

**DEVELOPMENT COMMITTEE**
Jerzy Gajewski, MD, Chair  
Julie Franc-Guimond, MD  
Hassan Razvi, MD  
D. Robert Siemens, MD

**HEALTH POLICY COMMITTEE**
Ronald Kaufman, Jr., MD, Chair  
Timothy Averch, MD  
David Albala, MD  
Louis D’Agostino, MD

**INVESTMENT COMMITTEE**
D. Robert Siemens, MD, Chair  
Kenneth Pace, MD  
Hassan Razvi, MD  
J.C. Trussel, MD

**JUDICIAL COMMITTEE**
Hassan Razvi, MD  
Anne-Marie Houle, MD  
Joel Nelson, MD

**NOMINATING COMMITTEE**
Jerzy Gajewski, MD, Chair  
Darren Beiko, MD  
Ronald Rabinowitz, MD  
Hassan Razvi, MD  
Oleg Shapiro, MD

**SCIENTIFIC PROGRAM COMMITTEE**
Julie Franc-Guimond, MD, Chair, NSAUA  
Wassim Kassouf, MD, Chair, QUA  
Sero Andonian, MD  
Timothy Averch, MD  
Naeem Bhojani, MD  
Thomas Fuller, MD  
Badar Mian, MD  
Geneviève Nadeau, MD  
Ricardo Rendon, MD  
Michelle Semins, MD

**SCHOLARSHIP RESEARCH COMMITTEE**
Jehonathan Pinthus, MD, Chair  
Jeffrey Gingrich, MD  
Wassim Kassouf, MD  
Guan Wu, MD
<table>
<thead>
<tr>
<th>YEAR</th>
<th>PRESIDENT</th>
<th>HOME CITY</th>
<th>MEETING SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1948-1949</td>
<td>James C. McClelland*</td>
<td>Toronto ON</td>
<td>Bigwin Inn, Huntsville, ON</td>
</tr>
<tr>
<td>1949-1950</td>
<td>A. Lawrence Parlow*</td>
<td>Rochester, NY</td>
<td>The Sagamore, Lake George, NY</td>
</tr>
<tr>
<td>1950-1951</td>
<td>William J. Kennedy*</td>
<td>Gloversville, NY</td>
<td>Lake Placid Club, Lake Placid NY</td>
</tr>
<tr>
<td>1951-1952</td>
<td>William A. Barrett*</td>
<td>Pittsburgh, PA</td>
<td>Hamilton Princess, Bermuda</td>
</tr>
<tr>
<td>1952-1953</td>
<td>David R. Mitchell*</td>
<td>Toronto, ON</td>
<td>Shawnee Inn, Shawnee on Delaware, PA</td>
</tr>
<tr>
<td>1953-1954</td>
<td>Albert M. Crance*</td>
<td>Geneva, NY</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1954-1955</td>
<td>Walter J. Hayward*</td>
<td>Jamestown, NY</td>
<td>Lake Placid Club, Lake Placid NY</td>
</tr>
<tr>
<td>1955-1956</td>
<td>William Baurys*</td>
<td>Sayre, PA</td>
<td>Equinox House, Manchester VT</td>
</tr>
<tr>
<td>1956-1957</td>
<td>Allan B. Hawthorne*</td>
<td>Montreal, QC</td>
<td>Whiteface Inn, Lake Placid NY</td>
</tr>
<tr>
<td>1957-1958</td>
<td>William A. Milner*</td>
<td>Albany, NY</td>
<td>Equinox House, Manchester, VT</td>
</tr>
<tr>
<td>1958-1959</td>
<td>S. H. Johnson III*</td>
<td>Pittsburgh, PA</td>
<td>Seignory Club, Montebello, QC</td>
</tr>
<tr>
<td>1959-1960</td>
<td>Frances O. Harbach*</td>
<td>Syracuse, NY</td>
<td>Bedford Springs Resort, Harrisburg, PA</td>
</tr>
<tr>
<td>1960-1961</td>
<td>J. Victor Berry*</td>
<td>Utica, NY</td>
<td>Grossinger’s, Liberty, NY</td>
</tr>
<tr>
<td>1961-1962</td>
<td>John S. Fitzgerald*</td>
<td>Scranton, PA</td>
<td>Shawnee Inn, Shawnee on Delaware, PA</td>
</tr>
<tr>
<td>1962-1963</td>
<td>Hollister W. Lyon*</td>
<td>Punxsutawney, PA</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1963-1964</td>
<td>John A. Benjamin*</td>
<td>Rochester, NY</td>
<td>Pocono Manor, Pocono Manor, PA</td>
</tr>
<tr>
<td>1964-1965</td>
<td>Arthur Bedard*</td>
<td>Quebec City, QC</td>
<td>Otesaga Hotel, Cooperstown NY</td>
</tr>
<tr>
<td>1965-1966</td>
<td>Michael G. O’Brien*</td>
<td>Scranton, PA</td>
<td>Shawnee Inn, Shawnee on Delaware, PA</td>
</tr>
<tr>
<td>1967-1968</td>
<td>William E. Collins*</td>
<td>Ottawa, ON</td>
<td>Whiteface Inn, Lake Placid NY</td>
</tr>
<tr>
<td>1968-1969</td>
<td>David W. Kline*</td>
<td>Greenville, PA</td>
<td>Whiteface Inn, Lake Placid NY</td>
</tr>
<tr>
<td>1970-1971</td>
<td>Charles L. Robson*</td>
<td>Toronto, ON</td>
<td>King’s Inn, Freeport, Grand Bahams</td>
</tr>
<tr>
<td>1971-1972</td>
<td>Charles C. Altman*</td>
<td>Pittsburgh, PA</td>
<td>Sheraton Hyannis, Cape Cod, MA</td>
</tr>
<tr>
<td>1972-1973</td>
<td>William J. Staubitz*</td>
<td>Buffalo, NY</td>
<td>Inn on the Park, Toronto, ON</td>
</tr>
<tr>
<td>1974-1975</td>
<td>Stuart E. Price*</td>
<td>Pittsburgh, PA</td>
<td>Buck Hill Inn, Buckingham, PA</td>
</tr>
<tr>
<td>1975-1976</td>
<td>Peter O. Crassweller</td>
<td>Toronto, ON</td>
<td>The Homestead, Hot Springs, VA</td>
</tr>
<tr>
<td>1976-1977</td>
<td>Otto M. Lilien*</td>
<td>Syracuse, NY</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1977-1978</td>
<td>John F. Rose, Jr.</td>
<td>Danville, PA</td>
<td>Lake Placid Club, Lake Placid NY</td>
</tr>
<tr>
<td>1978-1979</td>
<td>Andrew W. Bruce</td>
<td>Kingston, ON</td>
<td>Hotel Bonaventure, Montreal QC</td>
</tr>
<tr>
<td>1980-1981</td>
<td>Alan H. Irvine*</td>
<td>Ottawa, ON</td>
<td>Chateau Laurier Hotel, Ottawa, ON</td>
</tr>
<tr>
<td>1981-1982</td>
<td>Andre Vallieres</td>
<td>Quebec City, QC</td>
<td>The Nevele Country Club, Ellensburg NY</td>
</tr>
<tr>
<td>1982-1983</td>
<td>Leo M. King*</td>
<td>McKeesport, PA</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1984-1985</td>
<td>Martin Barkin</td>
<td>Toronto, ON</td>
<td>The Copley Plaza Westin Hotel, Boston MA</td>
</tr>
<tr>
<td>1985-1986</td>
<td>Pierre E. Bertrand</td>
<td>Quebec City, QC</td>
<td>The Four Seasons Hotel, Toronto, ON</td>
</tr>
<tr>
<td>1986-1987</td>
<td>David H. Barnhouse</td>
<td>Pittsburgh, PA</td>
<td>The Breakers, Palm Beach, FL</td>
</tr>
<tr>
<td>1987-1988</td>
<td>Grant A. Farrow</td>
<td>Toronto, ON</td>
<td>Hamilton Princess, Bermuda</td>
</tr>
<tr>
<td>1988-1989</td>
<td>Jack L. Sales</td>
<td>London, ON</td>
<td>Chateau Champlain, Montreal, QC</td>
</tr>
</tbody>
</table>

* Deceased
<table>
<thead>
<tr>
<th>YEAR</th>
<th>PRESIDENT</th>
<th>HOME CITY</th>
<th>MEETING SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1990-1991</td>
<td>Said A. Awad</td>
<td>Halifax, NS</td>
<td>Colonial Williamsburg, VA</td>
</tr>
<tr>
<td>1992-1993</td>
<td>Normand Sullivan*</td>
<td>St. Anne de Sorel, QC</td>
<td>El San Juan Hotel, San Juan, PR</td>
</tr>
<tr>
<td>1993-1994</td>
<td>Anthony V. Passaretti*</td>
<td>Albany, NY</td>
<td>The Sagamore, Lake George, NY</td>
</tr>
<tr>
<td>1994-1995</td>
<td>Mostafa M. Elhilali</td>
<td>Montreal, QC</td>
<td>Cairo Marriott Hotel, Cairo, Egypt</td>
</tr>
<tr>
<td>1995-1996</td>
<td>Ronald Rabinowitz</td>
<td>Rochester, NY</td>
<td>Buffalo Hilton, Buffalo, NY</td>
</tr>
<tr>
<td>1996-1997</td>
<td>David B. Patrick</td>
<td>Beaver, PA</td>
<td>Wigwam Resort, Phoenix, AZ</td>
</tr>
<tr>
<td>1997-1998</td>
<td>Alvaro Morales</td>
<td>Kingston, ON</td>
<td>Royal York Hotel, Toronto, ON</td>
</tr>
<tr>
<td>1998-1999</td>
<td>David J. Albert</td>
<td>Buffalo, NY</td>
<td>Southampton Princess, Bermuda</td>
</tr>
<tr>
<td>1999-2000</td>
<td>Kevin Pranikoff</td>
<td>Buffalo, NY</td>
<td>The Westin Hotel, Pittsburgh, PA</td>
</tr>
<tr>
<td>2000-2001</td>
<td>R. Brewer Auld</td>
<td>Halifax, NS</td>
<td>Boca Raton Resort, Boca Raton, FL</td>
</tr>
<tr>
<td>2001-2002</td>
<td>Datta G. Wagle</td>
<td>Williamsville, NY</td>
<td>Fairmont Mt. Tremblant, Mount Tremblant, QC</td>
</tr>
<tr>
<td>2003-2004</td>
<td>Mark F. Bellinger</td>
<td>Pittsburgh, PA</td>
<td>Westin Hotel, Savannah, GA</td>
</tr>
<tr>
<td>2004-2005</td>
<td>John D. Denstedt</td>
<td>London, ON</td>
<td>Southampton Princess, Bermuda</td>
</tr>
<tr>
<td>2005-2006</td>
<td>Gabriel P. Haas</td>
<td>Syracuse, NY</td>
<td>Westin Hotel, Ottawa, ON</td>
</tr>
<tr>
<td>2007-2008</td>
<td>James W. L. Wilson</td>
<td>Kingston, ON</td>
<td>Hyatt Tamaya, Santa Ana Pueblo, NM</td>
</tr>
<tr>
<td>2008-2009</td>
<td>Anne-Marie Houle</td>
<td>Montreal, QC</td>
<td>Fairmont Queen Elizabeth, Montreal QC</td>
</tr>
<tr>
<td>2009-2010</td>
<td>Joel B. Nelson</td>
<td>Pittsburgh, PA</td>
<td>Westin Convention Center Hotel, Pittsburgh, PA</td>
</tr>
<tr>
<td>2010-2011</td>
<td>Edward M. Messing</td>
<td>Rochester, NY</td>
<td>Roosevelt Hotel, New Orleans, LA</td>
</tr>
<tr>
<td>2011-2012</td>
<td>Hassan Razvi</td>
<td>London, ON</td>
<td>Scotiabank Convention Centre, Niagara Falls, NY</td>
</tr>
<tr>
<td>2012-2013</td>
<td>Zahi Makhul</td>
<td>Syracuse, NY</td>
<td>Saratoga Springs City Center, Saratoga Springs, NY</td>
</tr>
<tr>
<td>2013-2014</td>
<td>Jerzy Gajewski</td>
<td>Halifax, NS</td>
<td>Ritz Carlton Amelia Island, Amelia Island, FL</td>
</tr>
</tbody>
</table>

* Deceased

**PUBLICATION OF 2015 ABSTRACTS**

The Section is pleased to announce that all accepted abstracts of the 2015 annual meeting have been published in the September online issue of the Canadian Urological Association Journal (CUAJ).

The CUAJ is owned and officially endorsed by the Canadian Urological Association. CUAJ is a bi-monthly publication and is searchable on PubMed, with full-text articles on PubMed Central and on the newly created CUAJ website (www.cuaj.ca). The CUAJ is also covered in the Science Citation Index Expanded (also known as SciSearch) and the Journal Citation Reports/Science Edition provided by Thomson Reuters. Its recent impact factor is 1.92.

For additional information on submitting manuscripts or subscription information, contact:

**Josephine Sciortino**

Editorial Director, CUAJ

185 Dorval Ave., Suite 401, Dorval QC, Canada H9S 5J9

Tel: +1 514 395-0376, ext. 40
Fax: +1 514 395-1664
Email: josephine.sciortino@cua.org
Web: www.cuaj.ca
EXCERPT FROM THE WATERWAYS CHAPTER:

“No history of the Northeastern Section is complete without a short biography of this indefatigable urologist.

Dr. George E. Slotkin (1890-1971) was born in New York City but soon moved with his parents to Buffalo, NY, where he spent his professional career. We acknowledge him today as a founder, the first benefactor, and the first historian of the NS, but there is more to his story.

If one were to hold up a mirror to the changing face of urology in the first half of the 20th century, it would be well reflected with an image of George E. Slotkin. A graduate of the University of Buffalo Medical School, Dr. Slotkin did postgraduate work at the New York City Post Graduate Hospital, the University of Vienna, and the University of Budapest. In 1918, he became a clinical professor of urology at the University of Buffalo. During the late 1940s, his clinical interest was tuberculosis of the urinary tract, which he treated with chlamagoric acid. Even though results of his work in this area remain inconclusive, other fruits of his career do not. Friends and colleagues of his time were fond of saying, ‘George Slotkin has three loves: urology, his wife Helene, and his Rolls Royce...not necessarily in that order!’ His early work, ‘Nephroptosis, a resurrected disease,’ was published in The Urologic and Cutaneous Review in 1938. His later work with E.A. Mercer, ‘Case of epispadias with a double urethra,’ was published in The Journal of Urology in 1953.

Obviously, this change in his work reflects the change in urology from its early focus on genitourinary disease to its present focus as a surgical specialty. Dr. Slotkin was named Clinical Professor of Urology Emeritus in 1954 by the University of Buffalo Medical School and continued his private practice until 1964. After retirement, he continued to write, contributing a fascinating chapter about the history of the Northeastern Section to History of Urology. It is a priceless, logical record of carefully researched facts.

His obituary notice implies that he may have been the first American invited to join the Canadian Urological Association. Dr. and Mrs. Slotkin did not have any children; his estate included a generous bequest to the Northeastern Section to provide funding for invited guest speakers at our annual meetings.”


GEORGE E. SLOTKIN LECTURERS
1975 Prof. Willie L. M. Gregoir, MD, Brussels, Belgium
1976 J. Engelbert Dunphy, MD, San Francisco, California
1977 B. E. Christopher Nordin, MD, Leeds, England
1978 Donald Smith, MD, Piscataway, New Jersey
1979 J. Genest, MD, Montréal, Québec
1980 Joseph J. Kaufman, MD, Los Angeles, California
1982 Donald S. Coffey, MD, Baltimore, Maryland
1983 Martin I. Resnick, MD, Cleveland, Ohio
1984 Willet F Whitmore, Jr., MD, New York, New York
1985 Peter Scardino, MD, Houston, Texas
1986 William Fair, MD, New York, New York
1987 John Duckett, MD, Philadelphia, Pennsylvania
1989 Robert Jeffs, MD, Baltimore, Maryland
1990 Charles J. Devine, MD, Norfolk, Virginia
1991 Thomas Stamey, MD, Stanford, California
1992 Michael E. Mitchell, MD, Seattle, Washington
1993 Donald S. Coffey, MD, Baltimore, Maryland
1994 Carl Olsson, MD, Larchmont, New York
1995 Peter Scardino, MD, Houston, Texas
1996 Bernard M. Churchhill, MD, Los Angeles, California
1997 Peter R. Carroll, MD, San Francisco, California
1998 Joyce Lisa Tenover, MD, Atlanta, Georgia
1999 Richard D. Williams, MD, Iowa City, Iowa
2000 Gerry G. Blaivas, MD, New York, New York
2001 Alvaro Morales, MD, Kingston, Ontario
2002 Edson Pontes, MD, Detroit, Michigan
2003 Gerald L. Andriole, MD, St. Louis, Missouri
2004 Mustafa Elhilali, MD, Montréal, Québec
2005 Margaret Sue Pearle, MD, Dallas, Texas
2006 Mani Menon, MD, Detroit, Michigan
2007 Darius Jehan Bagli, MD, Toronto, Ontario
2008 S. Larry Goldenberg, MD, Vancouver, British Columbia
2009 Philip G. Ransley, MD, London, United Kingdom
2010 Joseph A. Smith, MD, Nashville, Tennessee
2011 Jean B. deKernion, MD, Los Angeles, California
2012 Michael A.S. Jewett, MD, Toronto, Ontario
2013 Barry A. Kogan, MD, Albany, New York
2014 Philipp Dahm, MD, Minneapolis, Minnesota
2015 GEORGE E. SLOTKIN LECTURER
John D. Denstedt, MD
London, Ontario
Chief, Department of Surgery and Professor, Department of Urology, Western University Special Advisor, Health Globalization, Internationalization & Simulation, Schulich School of Medicine & Dentistry
The Oncotype DX® GPS refines risk stratification in men with clinically low-risk prostate cancer, leading to greater confidence in treatment decisions.

Learn more at www.OncoTypeDX.com/prostate
CME INFORMATION & LEARNING OBJECTIVES

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Urological Association Education and Research, Inc. (AUAER) (hereafter AUA) and Northeastern Section of AUA (NSAUA). The AUA is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician Health Professionals: The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

• Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
• Limit content to evidence with no recommendations
• Introduction of a debate format with an unbiased moderator (point-counterpoint)
• Inclusion of moderated panel discussion
• Publication of a parallel or rebuttal article for an article that is felt to be biased
• Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
• Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA or NSAUA.

Consent to Use of Photographic Images: Registration and attendance at or participation in NSAUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside NSAUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this NSAUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The Northeastern Section complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Target Audience: The primary target audiences are AUA and Northeastern Section members, urology residents, urology subspecialty fellows and other members of the urologic care team.

Course Description: The 2015 Annual Meeting of the Northeastern Section will provide attendees with current updates on various urologic conditions and treatments including Urologic Cancers, Pediatrics, Testosterone Therapy, Urethral Trauma and OAB as well as an update on new AUA Guidelines. This year’s program provides diverse learning formats including plenary lectures, educational forums and debates and moderated poster sessions presented by many of Urology’s top experts. These different learning formats will allow attendees opportunities to improve their knowledge gaps and potentially change their practice patterns.
**Learning Objectives**: Upon completion of the 2015 NSAUA Annual Meeting, participants should be able to:

- Apply medical management of kidney stone guidelines into clinical practice.
- Recognize the current risk-based management of vesicoureteral reflux.
- Critically assess radiation exposure and radiation safety as it applies to their patients and themselves.
- Identify how to correctly diagnose mesh sling complications.
- Apply basic principles of social media into urology practice.
- Describe the options for management of recurrent male stress urinary incontinence and their success rates.
- Assess new therapies for BPH and recognize the role of metabolic dysfunction in managing male LUTS.
- Distinguish the current controversies regarding testosterone replacement therapy and cardiovascular issues.
- Outline an appropriate management strategy for refractory IC/PBS patients.

- Assess diagnosis and treatment of Peyronie's Disease as expressed in the newly released AUA Guideline.
- Review current evidences about effect and timing of hormone ablation in advanced prostate cancer.
- Examine the relationship between androgen deprivation therapy and cardiovascular disease.
- Review the treatment paradigm for bladder preservation and its evolution, the role of concurrent chemotherapy and the importance of early salvage cystectomy, when indicated.
- Evaluate the available evidence on lymphadenectomy in the management of upper tract urothelial cell carcinoma.
- Identify the risks and benefits of percutaneous biopsy of small renal masses.
- Define the role of PHI, 4Kscore, PCA3 and MRI in diagnosing prostate cancer.

Go to [NSAUA.org](http://NSAUA.org) to claim CME credits.

---

**VANCOUVER 2016**

71st Annual Meeting
June 25-28

Join us on the West Coast!
Au plaisir de vous voir sur la Côte-Ouest!

November 16, 2015 abstract submission opens
Early bird registration deadline: May 2, 2016
Hotel cut-off: May 31, 2016

[cuameeting.org](http://cuameeting.org)
THANK YOU TO OUR ANNUAL MEETING SUPPORTERS

The Northeastern Section thanks the following companies for providing educational grants in support of the 2015 Annual Meeting as of 10/7/15.

ABBVIE, INC.       AMERICAN MEDICAL SYSTEMS, INC.

The Northeastern Section thanks the following companies for their general support of the 2015 Annual Meeting as of 10/7/15.

DIAMOND LEVEL SUPPORTERS

FRIENDS LEVEL SUPPORTERS
Fun Night at Parliament
Friday, October 30, 2015
7 – 10 p.m.

Celebrate this year’s Annual Meeting with a Fun Night at Parliament! This exciting evening includes a tour of the beautiful and breathtaking Parliament building, dinner and entertainment by the Family Painchaud.

See page 32 for more information.
SEMA BURNEY, MBA, CPA, CA
Ms. Sema Burney is a human resources professional specializing in the areas of diversity and inclusion. Born and raised in Québec, by immigrant parents, Ms. Burney has always had a keen interest in cultural differences and has witnessed firsthand the changing face of our population. In 2010, she founded Burney Consulting, a boutique consulting firm offering services to organizations of varying sizes in both the private and public sectors, in areas such as Cross-Cultural Management, Leadership, Diversity and Inclusion. Throughout her career, Ms. Burney has been renowned for her positive attitude, her energy and her passion for people. As an experienced corporate trainer and an inspiring speaker, she has participated in numerous conferences, panel discussions and consultations lending her expertise in both English and French. In September 2011, she was invited to discuss the importance of diversity in the board of directors of the healthcare sector, along with several Québec Federal Ministers. She has also participated in conferences at Ste. Justine’s Hospital and for the Healthcare Businesswomen’s Association of Canada. In addition to her consulting work, she is currently a part-time lecturer at McGill University, teaching a graduate level course in Human Resources.

JASON A. EFSATHIOU, MD, DPHIL
Dr. Jason Efstathiou holds a BS from Yale University, a MD from Harvard Medical School (HMS), a DPhil from University of Oxford and completed his residency training in the Harvard Radiation Oncology Program. He serves as Associate Professor of Radiation Oncology at HMS and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology and Clinical Co-director of The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic at the Massachusetts General Hospital (MGH). His clinical practice focuses on bladder, prostate and other GU malignancies. A focus of his research has been on long-term outcomes and late toxicities following trimodality bladder-sparing chemoradiation for muscle-invasive bladder cancer which has helped inform clinical practice guidelines, as well as investigations into technology assessment and comparative effectiveness of emerging therapies for the treatment of GU cancers. He serves as Principal Investigator of multiple studies including a NCI-sponsored multi-center randomized phase III trial of advanced radiation technologies in prostate cancer using patient-reported outcomes. He holds leadership positions within the cooperative groups (serving as NRG Oncology Co-chair of Comparative Effectiveness, Study Co-chair of NRG-GU001 looking at post-cystectomy radiation and member of the GU and Advanced Technology Steering Committees), professional societies (serving as ASTRO GU Track Chair and a leader of the National Radiation Oncology Registry) and the National Cancer Institute where he serves as Co-chair of the Bladder Cancer Task Force.

SEAN P. ELLIOTT, MD
Dr. Sean Elliott is an Associate Professor, Vice Chair of Urology and Director of Reconstructive Urology at the University of Minnesota and Chief of Urology at Hennepin County Medical Center. He also directs a fellowship in Reconstructive Urology at the University of Minnesota. He completed a urology residency and fellowship in Genitourinary Trauma and Reconstruction at the University of California, San Francisco. He earned a Master’s of Science degree in Health Services Research at the University of Minnesota and completed the program in Leadership Development for Physicians in Academic Health Centers at Harvard University’s School of Public Health. Dr. Elliott’s clinical practice in Genitourinary Reconstruction includes urethral stricture disease, neurogenic bladder, long-term care of the adult with congenital urological problems, continent and non-continent urinary diversion and management of adverse effects of pelvic cancer therapy including impotence, bladder neck contracture, radiation cystitis and male stress urinary incontinence. Dr. Elliott is Secretary-Treasurer of the Society of Genitourinary Reconstructive Surgeons. He is a founding member of the Trauma and Urinary Reconstructive Network of Surgeons. His research has been funded by the National Institutes of Health, the Gillette Children’s Foundation, the Patient Centered Outcomes Research Institute and the American Cancer Society.

WAYNE J.G. HELLSTROM, MD
Dr. Wayne J. G. Hellstrom, a Fellow of the American College of Surgeons, is a Professor of Urology and Chief of Andrology at Tulane University School of Medicine in New Orleans, Louisiana. He works as a urologist at Tulane University, Charity Hospital and the Veterans Administration Medical Center in New Orleans. Dr. Hellstrom received his MD from McGill Medical School in Montréal, followed by a residency in General Surgery at McGill University in Montréal. He completed a residency in Urology at the University of California, San Francisco, and an AUA scholar-funded fellowship in Andrology at the University of California, Davis from 1986 to 1988. He is board certified in Urology. Dr. Hellstrom received the Young Andrologist Award by the ASA in 1994 and is a member of numerous professional societies, including the American Association of Genitourinary Surgeons, the Society for Male Reproduction and Société Internationale d’Urologie. He is the past President of the Sexual Medicine Society of North America and the American Society of Andrology. He is currently President of the International
Society of Sexual Medicine. Dr. Hellstrom’s research interests include male infertility, erectile dysfunction, prosthetic surgery, genitourinary reconstruction, sperm stimulation protocols for improving motion parameters of sperm, development of new vasoactive erection drugs in animal models, Peyronie’s disease (both basic research and clinical studies), development of new drugs treating premature ejaculation and male hormone deficiency. He also investigates gene therapy topics for the treatment of erectile dysfunction, Peyronie’s Disease and urethral stricture disease. Dr. Hellstrom has authored or coauthored over 100 book chapters and over 400 manuscripts in peer-reviewed journals. He has also delivered numerous presentations locally, nationally and internationally on various andrology subspecialty topics. He has instructed 20 fellows and has had many visiting students, residents and physicians.

Dr. Steven Kaplan received a BS in biochemistry from City University of New York - Brooklyn College in 1978 and graduated from Mount Sinai School of Medicine in 1982 and was elected to the AOA Honor Society. Dr. Kaplan’s postgraduate training included an internship and residency in the Department of Surgery at Mount Sinai Hospital as well as a residency in Urology at the Squier Urologic Clinic, Columbia University. He was an American Urological Association Scholar between 1988 – 1990 that focused on identifying molecular markers and urodynamic parameters that herald bladder and prostate dysfunction. Dr. Kaplan was the Given Foundation Professor of Urology and Administrator, as well as Vice Chairman of the Department of Urology at Columbia University from 1998 – 2005. Currently, Dr. Kaplan is the E. Darracott Vaughan, Jr. Professor of Urology and Chief, Institute for Bladder and Prostate Health at Weill Cornell Medical College and Director, Iris Cantor Men’s Health Center at New York Presbyterian Hospital. He has been Fellowship Director for Female Urology and Voiding Dysfunction from 1995 - 2005 at Columbia and at Weill Cornell Medical College since 2005. He is a serial entrepreneur and a founder of Medidata Solutions Inc., a publicly held corporation and one of the premier electronic data capture companies in the world; Medivizor, Inc., a medical informatics enterprise; and, Eco–Fusion, a novel health care interface and social media platform. Dr. Kaplan is a Diplomat of the American Board of Urology and a Fellow of the American College of Surgeons. He is a recognized authority on the study of benign diseases of the prostate, the association of metabolic factors and voiding dysfunction and female urology. He has published more than 880 articles, 170 abstracts and has made over 340 presentations in more than 35 countries. He is the co-author of five books and is on the Editorial Board of Urology, Journal of Urology, and Urology Times.

Dr. Brian Matlaga is Professor of Urology at the Johns Hopkins University School of Medicine and also serves as the Director of Ambulatory Care for the James Buchanan Brady Urological Institute. Dr. Matlaga received his undergraduate degree from Dartmouth College, and his MD and a Master of Public Health degree from Tulane University. He then completed his internship in surgery and residency in urology at Wake Forest University; his subsequent fellowship at Indiana University was supported by an American Foundation for Urologic Disease Research Scholarship. Dr. Matlaga is an internationally recognized expert in the medical and surgical management of patients with urinary stone disease, and he is the Director of Stone Disease for the Brady Urological Institute. This expertise is built on his academic investigations of the pathophysiology and epidemiology of stone formation, as well as into the advancement of minimally invasive surgical techniques. A frequent contributor to the medical press, Dr. Matlaga’s research has received both national and international awards; most recently, he was the recipient of the Endourological Society’s 2014 Arthur D. Smith Endourology Lectureship. Dr. Matlaga sits on numerous editorial boards as well as advisory committees and Guidelines Panels for the American Urological Association, the American Board of Urology, the Endourological Society and the National Institutes of Health.

Dr. Darryl Leong graduated from the University of Adelaide Medical School with Deans Listing and Honours for academic excellence in 2000. He completed his cardiology training, Doctor of Philosophy and Master of Biostatistics degrees at the University of Adelaide, Australia. He then completed a post-doctorate fellowship in cardiovascular imaging at the Leiden University Medical Centre, the Netherlands, before relocating to Canada. Dr. Leong has received a number of accolades, including the E.J. Moran Campbell Career Award, McMaster University, 2014, and he has published more than 80 articles in peer-reviewed journals including the Lancet and JAMA. Dr. Leong is leading the development of a research and clinical program for the evaluation and management of cardiovascular disease in patients with cancer and is co-principal investigator in RADICAL PC (a large prospective study of men with prostate cancer, funded by Prostate Cancer Canada). He also works in the Project Teams for the COMPASS trial and the PURE study. Dr. Leong is an Emerging Leader in the World Heart Federation.
focused in androgen receptor transcriptional activation and the minimally invasive techniques. His laboratory research has been on partial nephrectomy, and complex tumor resection, by open and robotic techniques. His clinical practice has focused upon radical prostatectomy, and he is internationally renowned as an expert in prostate cancer imaging, MRI-targeted prostate biopsy, and integration of MRI into clinical practice paradigms. He has lectured throughout the world on the use of prostate MRI in detection and therapy. He has served as Oncology Task Force Member and Chair, and Oncology Knowledge Assessment Test Co-Chair, for the American Board of Urology Exam Committee, Program Chair and Executive Committee Member for the Society of Urologic Oncology, and, most recently, Secretary General of the Urologic Research Society. He has authored over 150 articles, 25 book chapters, and 5 textbooks and periodicals on urologic cancer and urologic surgery. He is the Consulting Editor of the Urologic Clinics of North America and serves on the editorial board of European Urology. He is the previous Urology Surveys Upper Tract Oncology Editor, and the current Urology Surveys Prostate Cancer Editor for the Journal of Urology. He is editor of the 3rd, 4th, and upcoming 5th, editions of Taneja’s Complications of Urologic Surgery; Prevention and Diagnosis, one of the most widely read textbooks in American urology.

Dr. Anne K. Pelletier-Cameron received her undergraduate degree at the University of New Brunswick. After completing her medical degree at the University of Ottawa and residency in urology at Dalhousie University, she went to the University of Michigan for a fellowship in Female Pelvic Medicine and Reconstruction. Dr. Cameron remains at the University of Michigan where she is currently a Clinical Associate Professor of Urology and Director of the Clinical Urology Research Endeavor (CURE). Her clinical interests include complex incontinence, female urethral disease and the care of neurogenic bladder. Her research includes the care of neurogenic bladder, mesh complications and refractory overactive bladder.

Dr. Quoc-Dien Trinh is an Assistant Professor of Surgery at Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He is the core leader for ‘Guidelines and Effectiveness’ at the Center for Surgery and Public Health, a joint program of Harvard Medical School and the Harvard School of Public Health.

Dr. Trinh’s research focuses primarily on costs, patterns and outcomes of prostate cancer care, including robot-assisted procedures. His publications include over 300 peer-reviewed articles, book chapters, and videos. He currently serves as the Associate Editor for health services research at the British Journal of Urology (BJU) International. Dr. Trinh received his medical degree from the Université de Montréal in Montréal, Canada, where he also completed his residency training in Urology. He completed his fellowship in minimally invasive urologic oncology at the Vattikuti Urology Institute in Detroit, Michigan.

RESIDENTS & YOUNG UROLOGISTS BREAKFAST

Saturday, October 31, 2015, 7 – 8 a.m.

CULTURAL COMPETENCY IN HEALTHCARE

Join us for breakfast and this interactive session to learn why cultural understanding is important in medical practice.

Speaker: Sema Burney, McGill University

Open to all attendees
INVITED FACULTY – SECTION MEMBERS

JOHN D. DENSTEDT, MD
George E. Slotkin Lecturer
Dr. John Denstedt graduated from medical school at The University of Western Ontario in London, Canada. He completed his residency in Urology at Western between 1983 and 1987 followed by a fellowship in Endourology under Dr. Ralph Clayman at Washington University in St. Louis. He returned to London and joined the Division of Urology in the Department of Surgery at Western in 1990. In July 2003 he assumed the role of City-Wide Chair and Chief of the Department of Surgery at Western University and continues in this role. In October 2012, he was appointed Special Advisor to the Dean of the Schulich School of Medicine & Dentistry on Internationalization and Simulation. In May 2013, Dr. Denstedt joined the Board of Directors of the American Urological Association, becoming the 3rd Canadian in the organization’s history to do so. Dr. Denstedt is the immediate Past Chair of the Canadian Association of Surgical Chairs. While maintaining an active clinical practice, Dr. Denstedt is an internationally renowned scholar in urology with career accomplishments encompassing over 250 published papers and book chapters; more than 200 guest professorships in countries throughout the world; and numerous honours and awards including being the first Canadian to have won the Gold Cystoscope Award from the American Urological Association. Dr. Denstedt’s research interests include urolithiasis; biomaterials; and urinary tract infection. With a specific interest in surgical education, he has participated in the development and validation of computer based surgical simulators. Dr. Denstedt serves on the Editorial Board of seven journals in Urology, is currently Managing Editor of the Journal of Endourology and is the Treasurer of the Endourological Society.

JODI MARANCHIE, MD
University of Pittsburgh
Pittsburgh, PA

BADAR MIAN, MD
Albany Medical Center
Albany, NY

J. CURTIS NICKEL, MD
Queen’s University
Kingston, ON

RICARDO RENDON, MD
Dalhousie University
Halifax, NS

JO SEMINS, MD
University of Pittsburgh
Pittsburgh, PA

FRED SAAD, MD
University of Montréal
Montréal, QC

EDUCATIONAL FORUM CHAIRS

TIMOTHY AVERCH, MD
University of Pittsburgh
Pittsburgh, PA

WASSIM KASSOUF, MD
McGill University
Montréal, QC

GENEVIEVE NADEAU, MD
Laval University
Québec, QC

SERO ANDONIAN, MD
McGill University
Montréal, QC

RODNEY BREAUX, MD
University of Ottawa
Ottawa, ON

Vincent Fradet, MD
Laval University
Québec, QC

JOI MARANCHIE, MD
University of Pittsburgh
Pittsburgh, PA

BADAR MIAN, MD
Albany Medical Center
Albany, NY

J. CURTIS NICKEL, MD
Queen’s University
Kingston, ON

RICARDO RENDON, MD
Dalhousie University
Halifax, NS

JO SEMINS, MD
University of Pittsburgh
Pittsburgh, PA

FRED SAAD, MD
University of Montréal
Montréal, QC

EDUCATIONAL FORUM CHAIRS

TIMOTHY AVERCH, MD
University of Pittsburgh
Pittsburgh, PA

WASSIM KASSOUF, MD
McGill University
Montréal, QC

GENEVIEVE NADEAU, MD
Laval University
Québec, QC

SERO ANDONIAN, MD
McGill University
Montréal, QC

RODNEY BREAUX, MD
University of Ottawa
Ottawa, ON

Vincent Fradet, MD
Laval University
Québec, QC
MEETING ROOMS

General Session Room: Frontenac
Poster Session Rooms: Beauharnois & Montmagny

THURSDAY, OCTOBER 29, 2015

7:45 – 8:15 a.m.  Welcome Remarks
Joseph Greco, NSAUA President
Richard Babayan, AUA President-elect
Michael Leonard, CUA President
Jodi Maranchie, AUA Choosing Wisely 2015
Julie Franc-Guimond, Scientific Program Chair

PLENARY SESSION I: THE INTRUDERS
Moderator: Timothy Averch, University of Pittsburgh

8:15 – 9 a.m.  Educational Forum: Surgeon and Patient’s Safety – The X-Rays and Beyond
Sero Andonian, McGill University
Jo Semins, University of Pittsburgh

9 – 9:30 a.m.  Contemporary Medical Management of Urolithiasis: A Guidelines Based Approach
Brian Matlaga, Johns Hopkins University

9:30 – 10 a.m.  Bugs and Surgeons: Personal Lessons from the Urinary Tract
J. Curtis Nickel, Queen’s University

10 – 10:15 a.m.  Resident Debate: Percutaneous Approach vs. Ureteroscopy for Medium Size Stone
Moderator: Naeem Bhojani, University of Montréal

10:15 – 10:30 a.m.  Break

10:30 a.m. – Noon  Moderated Poster Session I: Laparoscopy/Robotics/Education
Beauharnois

Moderators: Sero Andonian, McGill University; Quoc-Dien Trinh, Harvard Medical School

10:30 a.m.  View Posters

10:45 a.m.  P1 – Extraperitoneal Robot-Assisted Laparoscopic Radical Prostatectomy: Outcomes in Very Large Prostates (> 100 g): A Matched Pair Analysis
Vineet Agrawal, Scott Quarry, Changyong Feng, Jean Joseph.
University of Rochester, Rochester, NY, USA.

10:48 a.m.  P2 – Outcomes of Robot-Assisted Repair of Diversion-Related Complications after Robot-Assisted Radical Cystectomy
Ahmed A. Hussein, Tareq Al-Tartir, Mohamed Sharif, Thomas Fiorica, Khurshid A. Guru.
Roswell Park Cancer Institute, Buffalo, NY, USA.

10:51 a.m.  P3 – Does Robot-Assisted Approach to Radical Cystectomy Deprive Patients of Continent Urinary Diversion?
Roswell Park Cancer Institute, Buffalo, NY, USA.

10:54 a.m.  P4 – Development and Validation of a Surgical Safety Checklist for Robot-Assisted Radical Cystectomy: From Airline to the Operating Room
1Roswell Park Cancer Institute, Buffalo, NY, USA,
2Guy’s Hospital and King’s College London School of Medicine, London, United Kingdom.

10:57 a.m.  P5 – Quality Performance Metrics for Robot-Assisted Radical Cystectomy: What have we Achieved in a Decade?
1Roswell Park Cancer Institute, Buffalo, NY, USA,
2Washington University School of Medicine, St. Louis, MO, USA,
3Onze-Lieve-Vrouw Ziekenhuis, Aalst, Belgium,
4University of Michigan, Ann Arbor, MI, USA,
5Wake Forest, Winston Salem, NC, USA,
6Weill Cornell Medical Center, New York, NY, USA,
7Urologic Surgical Associates of Delaware, Newark, DE, USA,
8Luigi Sacco, Milan, Italy,
9Cleveland Clinic Foundation, Cleveland, OH, USA,
10Fundacio Puigvert, Barcelona, Spain,
11Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of,
12The Arthur Smith Institute for Urology, New York, NY, USA,
13Memorial Şişli Hospital, Istanbul, Turkey,
14Henry Ford Health System, Detroit, MI, USA,
11 a.m.  P6 – The Loud Surgeon Behind the Console: A Methodology for Understanding Team Communication in Robot-Assisted Surgery
Judith Tiferes¹, Ann M. Bisantz², Mohamed A. Sharif³, Ahmed A. Hussein⁴, Nathalie M. Winder⁵, Khurshid A. Guru⁶.
¹The State University of New York, Buffalo, NY, USA, ²Roswell Park Cancer Institute, Buffalo, NY, USA.

10:51 a.m.  P15 – Compliance To Antimuscarinics In Children With Overactive Bladder
Valérie Morin, Alexandra Fortin, Pascale Gervais, Stéphane Bolduc.
CHU de Québec, Québec, QC, Canada.

10:54 a.m.  P16 – Is The Use Of Small Stents Safe In Following Pyeloplasty? Our Experience With 3 French Stents
Audry Kang¹, Andres F. Correa¹, Pankaj Dange², Heidi Stephany³, Glenn M. Cannon³, Francis X. Schneck³, Michael C. Ost².
¹University of Pittsburgh, Pittsburgh, PA, USA, ²University of Pittsburgh Childrens Hospital, Pittsburgh, PA, USA.

10:57 a.m.  P17 – Prize-Winning Essay: 3rd Place
Dual Therapy for Refractory Overactive Bladder in Children: a Prospective Open-label Study
Fannie Morin, Anne-Sophie Blais, Geneviève Nadeau, Katherine Moore, Lucie Genois, Stéphane Bolduc.
CHU de Québec-Université Laval, Québec, QC, Canada.

11 a.m.  P18 – Assessment Of Operative Strategies Using A Multidisciplinary Approach To Care For Pregnant Patients With Suspected Placental Anomalies - The Urologist’s Perspective
Valérie Hogues, Yann Chaussy, Anne-Marie Houle, Diego Barrières, Julie Franc-Guimond.
CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada.

11:03 a.m.  P19 – Same Day Anterior Urethroplasty is Feasible in Most Patients
Jeremy Reese, Katherine Theisen, Mang Chen.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
11:06 a.m. P20 – Patients Adherence to the Symptom-Based Follow-up Protocol after Urethral Reconstruction

Jeffrey Spencer, Dmitriy Nikolavsky.

SUNY Upstate Medical University, Syracuse, NY, USA.

11:09 a.m. P21 – Salvage Reconstruction For Failed Neourethra In Female To Male Gender Reassignment

Mourad Abouelleil, Jared Manwaring, Stephen Blakely, Dmitriy Nikolavsky.

Upstate, Syracuse, NY, USA.

11:12 a.m. P22 – Dorsal Onlay Urethroplasty For Membranous Urethral Strictures: Urinary And Erectile Functional Outcomes

Stephen Blakely, Mourad Abouelleil, Jared Manwaring, Tiffany Caza, Dmitriy Nikolavsky, Steve Landas.

Upstate, Syracuse, NY, USA.

11:15 a.m. P23 – Clinical and Patient Reported Outcomes of Urethroplasty for Long Segment or Panurethral Strictures

Jeffrey Spencer, Dmitriy Nikolavsky.

SUNY Upstate Medical University, Syracuse, NY, USA.

11:18 a.m. P24 – Gluing of Urologic Fistulas: A Viable Option In High Risk Patients


University of Rochester, Rochester, NY, USA.

11:21 a.m. P25 – The Treatment Of Recurrent Incontinence After A Failed Midurethral Sling: A Population-based Analysis

Blayne Welk¹, Jennifer Winick-Ng².

¹Western University, London, ON, Canada; ²ICES Western, London, ON, Canada.

11:24 a.m. P26 – Positive Outcomes After First Treatment with OnabotulinumtoxinA Persist Long-term With Repeat Treatments in Patients with Neurogenic Detrusor Overactivity

Philip Aliotta¹, Roger Dmochowski², Pierre Denys³, David Castro-Díaz⁴, Bertil Blok⁵, KarenEthans⁶, Manher Joshi⁷, Andrew Magyar⁶, Michael Kennelly⁷.

¹Western New York Urology Associates, LLC, Cheektowaga, NY, USA; ²Vanderbilt University Medical Center, Nashville, TN, USA; ³Hôpital Raymond Poincaré, Garches, France; ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; ⁵Erasmus Medical Center, Rotterdam, Netherlands; ⁶University of Manitoba, Winnipeg, MB, Canada; ⁷Allergan, Inc., Irvine, CA, USA; ⁸Allergan, Inc., Bridgewater, NJ, USA; ⁹Carolinas Rehabilitation, Charlotte, NC, USA.

11:27 a.m. P27 – Durable Improvements in Urinary Incontinence and Positive Treatment Response in Patients with Overactive Bladder Syndrome Following Long-Term OnabotulinumtoxinA Treatment: Final Results of 3.5-Year Study

Sidney Radomski¹, Dirk De Ridder², Christopher Chapple³, David Sussman⁴, Peter Sand⁵, Karl-Dietrich Sievert⁶, Brenda Jenkins⁷, Andrew Magyar⁶, Andrew Magyar⁶, Victor Nitti⁵.

¹University of Toronto, Toronto, ON, Canada; ²University Hospitals KU Leuven, Leuven, Belgium; ³Royal Hallamshire Hospital, Sheffield, United Kingdom; ⁴Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; ⁵Evaston Continence Center, Evanston, IL, USA; ⁶Paracelsus Medical University, Salzburg, Austria; ⁷Allergan, Inc., Irvine, CA, USA; ⁸Allergan, Inc., Bridgewater, NJ, USA; ⁹New York University, New York, NY, USA.

11:30 a.m. P28 – Botulinum Toxin Injections for Neurogenic Bladder: 3 year Urodynamic Outcomes

Gabriel Z. Leinwand¹, Ahmed Alkaram², Paul J. Feustel³, Elise J. B. De².

¹Albany Medical College, Albany, NY, USA; ²Albany Medical Center, Albany, NY, USA.

11:33 a.m. P29 – Electrical Stimulation of Afferent Nerves in the Foot with Transcutaneous Adhesive Pad Electrodes Improves Overactive Bladder Symptoms

Christopher Chermansky¹, Mang Chee¹, Jeremy Reese¹, Shachi Tyagi², Bing Shen³, Janet Okonski⁴, William de Groat¹, Changfeng Tai¹.

¹University of Pittsburgh School Of Medicine - Department of Urology, Pittsburgh, PA, USA; ²University of Pittsburgh School Of Medicine - Geriatrics Division in Department of Medicine, Pittsburgh, PA, USA; ³University of Pittsburgh School Of Medicine - Pharmacology and Chemical biology, Pittsburgh, PA, USA.

11:36 a.m. P30 – Photoselective Laser Vaporization Of The Prostate With Greenlight Xps Is Safe And Effective In High Risk Men With Symptomatic Benign Prostatic Hypertrophy

Emad S. Rajhi¹, Kevin Zorn¹, Ricardo Gonzalez¹, Gregg Eure¹, Lewis Kriteman¹, Mahmood Hai¹.

¹University of Montréal, Montréal, QC, Canada; ²Houston Metro Urology, Houston, TX, USA; ³Urology of Virginia, virginia, OH, USA; ⁴Georgia Urology, Atlanta, GA, USA; ⁵The Surgical Institute of Michigan, Ann Arbor, MI, USA.

11:39 a.m. P31 – Holmium:yag Laser Ablation For Management Of Lower Urinary Tract Surgical Mesh Or Suture Erosion Following Continence Surgery

Adiel Mamut¹, Paul Martin², Blayne Welk¹.

¹Western University, London, ON, Canada; ²Bluewater Health, Sarnia, ON, Canada.

Lunch Symposium

XTANDI (enzalutamide) capsules in the Urology Practice: Continuing Care for Your Patients with Metastatic CRPC

Liam Hurley, MD, FACS

Northeast Urologic Surgery, P.C. North Andover, MA

Sponsored by: Astellas Pharma US, Inc. and Medivation, Inc.
THURSDAY

1 - 1:45 p.m.  Exhibit Hall Sneak Peek Dessert Reception
Stone Extraction Challenge

PLENARY SESSION II: FAMILY & FRIENDS
Moderator: Anne-Marie Houle, University of Montréal

1:45 – 2:15 p.m.  Vesicoureteral Reflux: Current Risk Based Management
Paul Merguerian, Seattle Children’s Hospital

2:15 – 2:45 p.m.  Mesh Sling Complications: Diagnosis and Treatment
Anne Pelletier-Cameron, University of Michigan

2:45 – 3:15 p.m.  Social Media in Urology
Quoc-Dien Trinh, Harvard Medical School

3:15 – 3:30 p.m.  Break in Exhibit Hall

3:30 – 5 p.m.  Moderated Poster Session III: Oncology 1
Montmagny
Moderators: Badar Mian, Albany Medical Center; Jean-Baptiste Lattoufe, University of Montréal

3:30 p.m.  View Posters

3:45 p.m.  P32 – Pathologic Evaluation Of Non-tumor Renal Tissue Predicts Renal Function Post Radical Nephrectomy
Adiel Mamut, Gena Ibrahim, Fulan Cui, Neal Rowe, Patrick Luke, Madeleine Moussa.

3:48 p.m.  P33 – Performance Of CCP Assay In An Updated Series Of Biopsy Samples Obtained From Commercial Testing
E. David Crawford, Neal Shore, Peter T. Scardino, John W. Davis, Jonathan D. Tward, Lowndes Harrison, Brent Evans, Lisa FitzGerald, Steven Stone, Michael K. Braver.

3:51 p.m.  P34 – Partial and Hemi-Nephrectomy for Renal Malignancy in Patients with Horseshoe Kidney
Todd S. Yecies, Matthew Ferroni, Bruce Jacobs, Robert Turner, Ronald Hrebinko.

3:54 p.m.  P35 – A Multi-center Comparison Of A 17-gene Genomic Prostate Score (GPS) As A Predictor Of Outcomes In African-American (AA) And Caucasian (CA) Men With Clinically Localized Prostate Cancer (PCa)
James Mohler, Jennifer Cullen, Isabella Sesterhenn, Shiv Srivastava, Eric Klein, Peter Carroll, Matthew Cooperberg, Tara Maddala, Dejan Knezevic, Athanasios Tsiatis, Jeffrey Lawrence, Philip Febo.

3:57 p.m.  P36 – Use of the Genitourinary Pain Index (GUPI) to Quantify Symptoms Associated with Bacillus Calmette-Guerin Treatment for Non-Muscle Invasive Bladder Cancer
Matthew C. Ferroni, Robert M. Turner, Il, Timothy D. Lyon, Cameron Jones, Benjamin J. Davies, Bruce L. Jacobs.

4 p.m.  P37 – Clinical and Pathological Implications of Cautery Artifact Associated with Transurethral Resection of Large Bladder Tumors

4:03 p.m.  P38 – Four Birds One Stone to Inhibit 5androstane-3β,17β-diol Conversion to DHT
Michael V. Fiandalo, John Wilton, John J. Stocking, Yun Li, Elizabeth M. Wilson, James L. Mohler.

4:06 p.m.  P39 – Does Dose Reduction of Neoadjuvant Chemotherapy Impact Perioperative Outcomes after Robot-Assisted Radical Cystectomy?

Roswell Park Cancer Institute, Buffalo, NY, USA.
3:57 p.m. P53 – Ureteric Stricture Following Ureteral
Access Sheaths in the Modern Era: How Rare is
it?
Kenneth T. Pace, Abdalaziz M. Althunayan, Daniela
Ghiculete, Jason Y. Lee, Michael Ordon, R.J. D’A
Honey.
St. Michael’s Hospital, University of Toronto, Toronto,
ON, Canada.

4 p.m. P54 – Preoperative Patient and Stone
Characteristics Associated with a Prolonged
Length of Hospital Stay Following Tubeless
PCNL
Keith Barrett, Daniela Ghiculete, Kenneth T. Pace,
St. Michael’s Hospital, University of Toronto, Toronto,
ON, Canada.

4:03 p.m. P55 – Randomized Controlled Trial of Two
Vitamin D Repletion Protocols to Assess Impact
on Calcium Excretion in Stone Formers
Matthew C. Ferroni, Kevin J. Rycyna, Andres F.
Correa, Timothy D. Averch, Michelle J. Semins.
University of Pittsburgh Medical Center, Pittsburgh,
PA, USA.

4:06 p.m. P56 – 180w Photoselective Vaporization
Of The Prostate (pvp) For Benign Prostatic
Hyperplasia: Assessing The Learning Curve
Hugo Lavigueur-Blouin, Côme Tholomier, Roger
Valdivieso, Pierre-Alain Hueber, Vincent Trudeau,
Marc Nicolas Bienz, Kevin C. Zorn, Kevin C. Zorn.
Centre hospitalier de l’Université de Montréal,
Montréal, QC, Canada.

4:09 p.m. P57 – Satellite Rural Ambulatory Urology Clinics
– 25 Years Later
Emmanuel O. Abara.
Kirkland and District Hospital, Kirkland Lake, ON,
Canada.

4:12 p.m. P58 – Defining a Meaningful Clinical Change
in a Patient’s American Urologic Association
Symptom Index (AUA-SI)
Thomas W. Fuller, Benjamin T. Ristau, Sushil Beriwal,
Ronald M. Benoit.
University of Pittsburgh Medical Center, Pittsburgh,
PA, USA.

4:15 p.m. P59 – Milestones in Canadian Urology
Jerzy Gajewski.
Dalhousie University, Halifax, NS, Canada.

4:18 p.m. P60 – The Relationship of Physician Payments
from Drug Manufacturers to Prior Degarelix and
Denosumab Medicare Billing Volume
Jathin Bandari¹, David Canes², Ali Moinzadeh³, Robert
Turner, Benjamin Davies³.
¹University of Pittsburgh, Pittsburgh, PA, USA, ²Lahey
Clinic, Burlington, MA, USA.

4:21 p.m. P61 – The Utility of Sex Hormone Binding
Globulin in Infertile Males
Joseph Mahon⁴, R. Charles Welliver⁵, Casey Lythgoe⁶,
Mike Parenteau⁴, Stephen Markwell⁷, Robert E.
Brannigan¹, Tobias S. Kohler⁴.
¹Albany Medical Center, Albany, NY, USA, ²Southern
Indiana University, Springfield, IN, USA, ³Southern
Indiana University, Springfield, IL, USA.
PLENARY SESSION III: THE MALE FACTOR

Moderator: Naeem Bhojani, University of Montréal

8 – 8:30 a.m.  
Reoperation for Male Stress Urinary Incontinence  
Sean Elliott, University of Minnesota

8:30 - 9 a.m.  
Prostate Cancer: Not Every Male is Managed the Same  
Quoc-Dien Trinh, Harvard Medical School

9 – 9:30 a.m.  
BPH: Trends and Recommendations  
Steven Kaplan, Weill Cornell Medical College

9:30 - 10 a.m.  
Break in Exhibit Hall

10 - 11 a.m.  
AUA Course of Choice  
Moderator: Julie Franc-Guimond, University of Montréal

Contemporary Issues in Testosterone Deficiency: Diagnosis and Management  
Wayne Hellstrom, Tulane University

11 a.m. – 12:30 p.m.  
Moderated Poster Session V: Oncology 2

Montmagny  
Moderators: Rodny Breau, University of Ottawa; Jason Efstathiou, Harvard Medical School

11 a.m.  
View Posters

11:15 a.m.  
P65 – Budget Impact Model for the Utilization of PCA 3 Urine Testing in Prostate Cancer Screening  
Charles O. Kim, Jr.  
University of Hawaii, Honolulu, HI, USA.

11:18 a.m.  
P66 – Radiotherapy With Androgen Deprivation Therapy For High-risk Prostate Cancer- The Centre Hospitalier De l’Université De Montréal Experience  
Daniel Taussky, Maroie Barkati, Carole Lambert, Marie-Claude Beauchemin, Marie-Claude Beauchemin, Jean-Paul Bahary, Guila Delouya.  
Université de Montréal, Montréal, QC, Canada.

11:21 a.m.  
P67 – Short-term Outcomes of Intraoperative Cell Saver® Transfusion during Open Partial Nephrectomy  
Timothy D. Lyon1, Matthew C. Ferroni1, Robert M. Turner II, Cameron Jones2, Bruce L. Jacobs3, Benjamin J. Davies4.  
1Department of Urology, University of Pittsburgh, Pittsburgh, PA, USA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

11:24 a.m.  
P68 – Value of Magnetic Resonance Imaging-Ultrasound Fusion as the Initial Prostate Biopsy  
Ramkishen Narayanan1, Michael Duff2, David Cipolla3, Joseph Greco4, John Schrecengost4, Margaret Sura5, K. Kent Cherv6.  
1State University of New York at Buffalo, Buffalo, NY, USA; 2Cancer Care of Western New York, Cheektowaga, NY, USA; 3Great Lakes Medical Imaging, Cheektowaga, NY, USA; 4Western New York Urology Associates, LLC, Cheektowaga, NY, USA.

11:27 a.m.  
P69 – Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients  
Fred Saad1, Joan Carles1, Silke Gilles1, Daniel Heinrich1, Jeremy Gratt1, Kurt Miller2, Sten Nilsson3, Joe M. O’Sullivan4, Marcello Tucci5, Manfred Wirth6, Axel Heidenreich7.  
1University of Montréal Hospital Center, Montréal, QC, Canada; 2Vall Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain; 3Kantonsspital St Gallen, St Gallen, Switzerland; 4Akershus University Hospital, Lørenskog, Norway; 5Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA; 6Department of Urology, Charité Berlin, Berlin, Germany; 7Karolinska University Hospital, Stockholm, Sweden; 8Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom; 9San Luigi Hospital, Department of Oncology, Orbassano (Turin), Italy; 10University Hospital Carl-Gustav Carus, Dresden, Germany; 11University Hospital, RWTH Aachen, Aachen, Germany.

11:30 a.m.  
P70 – Impact of Pathology Review On Clinical Management Of Patients With Bladder Cancer  
Samer L. Traboulsi, Fadi Brimo, Simon Tanguay, Armin Aprikian, Wassim Kassouf.  
McGill University Health Centre, Montréal, QC, Canada.

11:33 a.m.  
P71 – Clinical Utility of a 17-gene Genomic Prostate Score (GPS) for Treatment Selection in Men with Newly Diagnosed Prostate Cancer (PCa)  
Marc Dall’Era1, Bela Denes2, Jeffrey Lawrence3, Athanasios Tsialis4, Megan Rothney2, Tara Maddala2, Phillip Fetto2, Ketan Badani2.  
1University of California, Davis, Sacramento, CA, USA; 2Genomic Health, Redwood City, CA, USA; 3Mt Sinai, New York, NY, USA.
11:36 a.m.  P72 – A Comparison of Morbidity of Salvage Whole Gland Cryosurgery and High Intensity Focused Ultrasound For Radio-recurrent Prostate Cancer
Khurram M. Siddiqui\textsuperscript{1}, Michele Billia\textsuperscript{1}, Ali Alzahrani\textsuperscript{2}, Andrew Williams\textsuperscript{3}, Joseph Chiri\textsuperscript{1}.
\textsuperscript{1}University of Western Ontario, London, ON, Canada, \textsuperscript{2}University of Dammam, Dammam, Saudi Arabia.

11:39 a.m.  P73 – Lymph Node Counts are Valid Indicators of the Quality of Surgical Care in Bladder Cancer: A Population-Based Study
D. Robert Siemens, William MacKillop, Xuejiao Wei, Chris Booth.
Queen's University, Kingston, ON, Canada.

11:42 a.m.  P74 – Cytogenetics as a Diagnostic Aid for Genitourinary Liposarcoma
Lee A. Hugar, Gabriela M. Quiroga-Garza, Benjamin J. Davies, Ronald L. Hrebinko, Bruce L. Jacobs.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

11:45 a.m.  P75 – Effect of Multimodal Analgesia with Paravertebral Blocks on Biochemical Recurrence in Men Undergoing Open Radical Prostatectomy
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

11:48 a.m.  P76 – Risk Factors And Timing Of Venous Thromboembolism After Cystectomy In Routine Clinical Practice: A Population Based Study
R. Christopher Doiron, Christopher M. Booth, Xuejiao Wei, D. Robert Siemens.
Queen's University, Kingston, ON, Canada.

11:51 a.m.  P77 – Effects Of Surgeon And Patient Gender On Type Of Nephrectomy Performed
Igor Sorokin, Paul Feustel, Rebecca O’Malley.
Albany Medical Center, Albany, NY, USA.

11:54 a.m.  P78 – Clinical Predictors for Upgrading of Biopsy Gleason Sum 3+4 Prostate Cancer
Daniel T. Keefe\textsuperscript{1}, Trevor Flood\textsuperscript{2}, Rodney H. Breaux\textsuperscript{3}, Ilias Cagiannos\textsuperscript{4}, Chris Morash\textsuperscript{1}, Nicola Schieda\textsuperscript{1}.
\textsuperscript{1}Division of Urology, University of Ottawa, Ottawa, ON, Canada, \textsuperscript{2}Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada, \textsuperscript{3}Department of Radiology, University of Ottawa, Ottawa, ON, Canada.

11:57 a.m.  P79 – Neoadjuvant Chemotherapy Prior to Cystectomy is Not Associated with Increased Postoperative Complication Rates Compared to Cystectomy Alone
Helen R. Levey Bernie, Anees Fazili, Jacob Gantz, Phillip Rappold, Thomas Osinski, Edward Messing.
University of Rochester, Rochester, NY, USA.

12 p.m.  P80 – Clinical Features of Prostate Cancer in Confirmed BRCA2 Mutation Carriers
Stephanie Gleicher, Gennady Bratalsky, Srivinas Vourganti.
SUNY Upstate Medical University, Syracuse, NY, USA.

11 a.m. – 12:30 p.m.  Moderated Poster Session VI: Basic Science
Beauharnois
Moderators: Jodi Maranchie, University of Pittsburgh; Vincent Fradet, Laval University

View Posters

11 a.m.  P81 – Development Of A Sensitive Molecular Imaging System Based On The Transcriptional Activity Of The Peg3 Gene (progression Elevated Gene-3) To Image Castration-resistant Prostate Cancer Cells
Pallavi Jain, Bertrand Neveu, Yves Fradet, Frederic Pouliot.
University Laval, Quebec City, QC, Canada.

11:18 a.m.  P82 – Gene Expression Profiling Distinguishes Stromal Phenotypes Associated With Gleason 3 Versus Gleason 4 Prostate Cancers
Ilinca Georgescu\textsuperscript{1}, R. Christopher Doiron\textsuperscript{2}, Victoria Tolls\textsuperscript{3}, J. Robert Gooding\textsuperscript{4}, Andrew Day\textsuperscript{2}, D. Robert Siemens\textsuperscript{2}, Paul C. Park\textsuperscript{2}.
\textsuperscript{1}Queen's University, Kingston, ON, Canada, \textsuperscript{2}NCIC Clinical Trials Group, Kingston, ON, Canada.

11:21 a.m.  P83 – On The Way to The Optimization Of The Bladder Tissue Engineering
Sara Bouhout, Stéphane Chabaud, Sophie Ramsay, Francine Goulet, Stéphane Bolduc.
Laval University, Quebec, QC, Canada.

11:24 a.m.  P84 – Hypoxia And Tissue Engineering In Urology
Stéphane Chabaud\textsuperscript{1}, Clément Baratange\textsuperscript{2}, Brice Boiroux\textsuperscript{3}, Sophie Ramsay\textsuperscript{2}, Alexandre Rousseau\textsuperscript{1}, Sara Bouhout\textsuperscript{1}, Stéphane Bolduc\textsuperscript{1}.
\textsuperscript{1}Laval University, Quebec, QC, Canada, \textsuperscript{2}Institut Universitaire de Technologie de Laval, Laval, France.

11:27 a.m.  P85 – Prize-Winning Essay: 2nd Place
Pudendal but not Tibial Neuromodulation Inhibits Efferent Output from Pontine Micturition Center in Cats
Timothy D. Lyon\textsuperscript{1}, Brian T. Kadow\textsuperscript{2}, Zhaocon Zang\textsuperscript{2}, Bing Shen\textsuperscript{2}, Jicheng Wang\textsuperscript{2}, Audry Kang\textsuperscript{1}, Andy Lee\textsuperscript{1}, James R. Roppolo\textsuperscript{2}, William C. de Groat\textsuperscript{2}, Changfeng Tai\textsuperscript{1}.
\textsuperscript{1}Department of Urology, University of Pittsburgh, Pittsburgh, PA, USA, \textsuperscript{2}Department of Urology, Qilu Hospital, Shandong University, Jinan, China, \textsuperscript{3}University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, \textsuperscript{4}Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
11:30 a.m. P86 – A PCA3 Gene-Based Transcriptional Amplification System Targeting Primary and Metastatic Prostate Cancer Cells
Pallavi Jain, Bertrand Neeveu, Yves Fradet, Frédéric Pouliot.
University Laval, Québec City, QC, Canada.

11:33 a.m. P87 – Combined Inhibition Of Wee1 Kinase And Heat Shock Protein-90 In The Treatment Of Urothelial Cancer
Mahmoud Chehab, Richard Cotran, Diana Dunn, Alossh Madala, Mark Woodford, Sami Jamal, Gennady Bratslavsky, Mehdi Mollapour, Dimitra Bourboulia.
Upstate Medical University, Syracuse, NY, USA.

11:36 a.m. P88 – 3-D In Vitro Urothelium Infection Model Using The Self-assembly Technique
Hazem Orabi1, Vitalie Railean2, Stephane Chabaud1, Stéphane Bolduc2.
1Urology Department, Université Laval, Québec, QC, Canada, 2LOEX, Université Laval, Québec, QC, Canada.

11:39 a.m. P89 – WITHDRAWN

11:42 a.m. P90 – MicroRNAs as Potential Biomarkers to Predict Risk of Urinary Retention Following Intradetrusor onabotulinumtoxin-A Injection
Brian Kadow, Christopher Chermansky, Mahendra Kashyap, Subrata Pore, Pradeep Tyagi.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

11:45 a.m. P91 – Hydrogen Sulfide Ameliorates Renal Injury Associated With Chronic Obstructive Uropathy
Shouzhe Lin1, Fazil Visram2, Ian Lobb1, Amy Mok1, Jifu Jiang1, Matthew Whiteman1, Weihua Liu2, Aaron Haig1, Alp Sener3.
1Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, 2Department of Physiology and Pharmacology, The University of Western Ontario, London, ON, Canada, 3Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada.

1:15 – 1:45 p.m. Educational Forum
Pain, Physical Disabilities, Technical Difficulties & Surgical Failures
Chair: Geneviève Nadeau
J. Curtis Nickel, Queen’s University
Sean Elliott, University of Minnesota
Anne Pelletier Cameron, University of Michigan
Steven Kaplan, Weill Cornell Medical College

1:45 – 3 p.m. Section Stars Session
Young Investigator Grant Recipient 2010
Vincent Fradet, Laval University

12:30 – 1:15 p.m. Lunch in Exhibit Hall

STONE EXTRATION CHALLENGE

PLENARY SESSION IV: THE CHALLENGES

1:15 – 1:45 p.m. George E. Slotkin Lecture
Moderator: Joseph Greco, Western NY Urology Associates
Trends in International Education: Implications for Northeastern Section Urologists and Trainees
John Denstedt, University of Western Ontario

1:45 – 3 p.m. AACU Update
Kevin Barlog, AACU Board of Directors

3:15 – 3:45 p.m. AUA Guidelines Update
Rodney Breau, University of Ottawa

3:15 – 3:45 p.m. AUA Guidelines Update
Rodney Breau, University of Ottawa

3:45 – 4:45 p.m. Section Stars Session
Young Investigator Grant Recipient 2010
Vincent Fradet, Laval University

Prize Winning Essays

First Place
Urinary Exosomes Contain Long Non-Coding RNA and May Function as Bladder Cancer Biomarkers
Claudia Berrondo, MD - University of Rochester

Second Place
Pudendal but not Tibial Neuromodulation Inhibits Efferent Output from Pontine Micturition Center in Cats
Timothy D. Lyon, MD – University of Pittsburgh

Third Place
Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study
Fannie Morin, MD - CHU de Québec-Université Laval

2015 IVUMed Scholar
Helen Levey Bernie, University of Rochester

Best of Poster Presentations

1:15 – 1:45 p.m. George E. Slotkin Lecture
Moderator: Joseph Greco, Western NY Urology Associates
Trends in International Education: Implications for Northeastern Section Urologists and Trainees
John Denstedt, University of Western Ontario

4:45 – 5:30 p.m. NSAUA Annual Business Meeting

7 – 10 p.m. Fun Night at Parliament
Buses depart at 6:30 p.m. Meet on Terrasse level (one floor below the lobby of the Fairmont hotel).
SATURDAY, OCTOBER 31, 2015

7 – 8 a.m.  Residents & Young Urologists Breakfast
            Salon Rose
            Cultural Competency in Healthcare
            Sema Burney, McGill University

NSAUA & QUA JOINT ONCOLOGY MEETING

Saturday’s scientific program will be a joint Uro-Oncology meeting of the Northeastern Section, AUA and the Québec Urological Association.

Earn up to 3.5 CME credits for Saturday’s joint oncology meeting.

PLENARY SESSION V: THE ENEMY – CANCER

8 – 8:05 a.m.  Opening Remarks

8:05 – 8:15 a.m.  Best of Oncology Posters

8:15 – 9:30 a.m.  Hormone Therapy in Prostate Cancer

Moderator: Gennady Bratslavsky, SUNY Upstate Medical University

8:15 – 8:40 a.m.  Hormone Ablation in Advanced Prostate Cancer: When and How

Vincent Fradet, Laval University

8:40 – 9:05 a.m.  Cardiovascular Disease and Androgen Deprivation Therapy – Perspectives of a Cardiologist and Epidemiologist

Darryl Leong, McMaster University

8:40 – 9:05 a.m.  Cardiovascular Disease and Androgen Deprivation Therapy – Perspectives of a Cardiologist and Epidemiologist

Darryl Leong, McMaster University

9:05 – 9:30 a.m.  Management of Castration Resistant Prostate Cancer in 2015 and Beyond

Fred Saad, University of Montréal

9:30 – 9:45 a.m.  Resident Debate

Management of Oligometastasis in Renal Cell Carcinoma: Surgical vs. SBRT

Moderator: Badar Mian, Albany Medical Center

9:45 – 10 a.m.  Break

10 – 10:30 a.m.  Current Status, Paradigms and Advances in Trimodality Bladder-Sparing Therapy for Muscle Invasive Bladder Cancer

Jason Efstathiou, Harvard Medical School

10:30 – 11:50 a.m.  Potpourri Educational Forum

Controversies in Urologic Cancers

Chair: Wassim Kassouf, McGill University

10:30 – 10:50 a.m.  Therapeutic Role of Lymphadenectomy in Upper Tract Urothelial Carcinoma

Ricardo Rendon, Dalhousie University

10:50 – 11:10 a.m.  Should All Patients with a Small Renal Mass Undergo a Biopsy?

Jodi Maranchie, University of Pittsburgh

11:10 – 11:30 a.m.  Management of Persistent Positive Cytology

Badar Mian, Albany Medical Center

11:30 – 11:50 a.m.  Do Patients with Elevated PSA Require Other Ancillary Tests Prior to Prostate Biopsy?

Samir Taneja, NYU Langone Medical Center

11:50 a.m. – Noon  Closing Remarks

Open Afternoon

See Tour Options on Page 31

6:30 – 10 p.m.  President’s Reception & Banquet

Frontenac

The Northeastern Section, thanks the Québec Urological Association for collaborating to provide this year’s joint Uro-Oncology Meeting.

QUA PROGRAM PLANNING COMMITTEE

Wassim Kassouf, MD, Chair

Martine Jolivet-Tremblay, MD

Julie Franc-Guimond, MD
EXHIBIT HALL GRAND OPENING RECEPTION
Thursday, October 29, 2015
6 – 7 p.m.
Fairmont Château Frontenac

Join us for networking, food, beverage, exciting giveaways and fun at the Grand Opening event. This evening you’ll feel very French, as a traditional French accordion player entertains us on the exhibit floor. Feel free to request a photo with him! Please be sure to visit the exhibitors on the floor to thank them for supporting our meeting. We couldn’t do it without them!

TOURS

The following tours have been reserved for guests on Thursday, October 29; Friday, October 30; and Saturday, October 31, 2015. Each tour group will meet in the main lobby of the Fairmont prior to departure. Guests are encouraged to pre-register for tours when they pre-register for the conference, as spots will go quickly. On-site tour registration will take place at the hotel on Wednesday, October 28, from 5 – 7 p.m., and Thursday, October 29, from 7 a.m. – 5:00 p.m. Tours will be available on a first-come, first-served basis. Payments can be made on site at the hotel for any tours that have not been pre-registered or prepaid.

Please note that if minimum registrations are not met, tours will be cancelled.

TOUR OPTION: FINE ARTS MUSEUM

THURSDAY, OCTOBER 29, 2015
The National Museum of Fine Arts of Quebec is located in National Battlefields Park, also known as the Plains of Abraham. This urban park is one of the most marvelous in the world. It has 108 hectares of plains, wooded areas and gardens. A green oasis in the heart of the city, it is visited each year by thousands of residents and visitors. The back of the museum provides a magnificent view of this space and the St. Lawrence River.

With its three pavilions, the museum provides you with a wide range of exhibitions promoting and preserving Québec art of all periods, from ancient art to contemporary art, and ensuring a place for international art through acquisitions, exhibitions and other cultural activities.

Tour time: 1:30 – 4 p.m.
Cost: $72 USD — includes museum entrance fees, a museum docent, transportation, gratuities and all applicable taxes

TOUR OPTION: ISLAND OF ORLEANS
FRIDAY, OCTOBER 30, 2015

The island is one of the earliest French settlements in North America. Its extensive shoreline offered fertile soils that were less arduous to clear. Its forest abounded with game, and the St. Lawrence River with fish. The river also protected the settlers from Iroquois raids. Over the years, more than 300 families settled on the island. It is hardly surprising that the Island of Orléans is now known as the cradle of French civilization in North America. You are invited to visit and discover two of the unique main attractions offered on the island.

The Domaine Steinbach is a bio-certified farm operation located on a 30-acre estate along the St. Lawrence River. In addition to the stone-built ancestral home and 4,000-tree orchard, the estate features a duck and goose husbandry, a vinegar factory and an interpretation centre with cooking facilities for the processing of Domaine-grown products. Heart-melting gift selections in their general store will provide you with the opportunity to bring back a piece of île d’Orléans charm.

The Manoir Mauvide-Genest, located in Saint-Jean on the Island of Orleans, is a Quebec interpretation site on the seigniorial regime of New France. It is the only one of its kind in North America—part of the network of historic monuments in Quebec. The building still includes the structures built at the time of Louis XV, and paints a detailed picture of the lives of settlers on the Island of Orleans in those days. Visitors can admire the furniture and costumes depicting life in New France through guided tours and multimedia shows.

Tour time: 9 a.m. – Noon
Cost: $55 USD — includes transportation, sightseeing tour, entrance fees to sites, gratuities and all applicable taxes

TOUR OPTION: DISCOVER QUEBEC, A HISTORICAL CITY

SATURDAY, OCTOBER 31, 2015

A must-do tour! For 400 years, the sun has risen and set over the cradle of French civilization in North America: Quebec City. Experience the European charm of Quebec City; visit the Upper and Lower Town districts; and discover the Latin Quarter, the Ramparts, and the main churches. Quebec City is a taste of Europe right here in North America.

Lunch at Le Cosmos Café – Cosmos Café is a local favorite. Family-friendly brunches, business lunches, dynamic cocktail hours, and late-night dinners all happen at this Grande-Allée icon. Dishes are generous and tasty. The best spot in town to start your Quebec Discovery.

Tour Time: Noon – 4 p.m.
Cost: $95 USD — includes transportation, tour guide, three-course lunch, gratuities and all applicable taxes.
5K FUN RUN

FRIDAY, OCTOBER 30, 2015
6:30 – 8 a.m.
Fairmont Château Frontenac

For runners and walkers, join us—and run or walk! Or, if you prefer, be a sleepwalker—stay in bed and contribute $25 to the Section’s Foundation in support of education and research grants for Residents.

The race will start on the Dufferin Terrace, go through the Plains of Abraham, and return to the Chateau.

You can pre-register for this event when you pre-register for the conference on the website, or you can register on site. Prizes will be given to the top three male and female runners.

Cost: $30 USD — includes t-shirt, race director, water and snacks.

PRESIDENT’S RECEPTION AND BANQUET

SATURDAY, OCTOBER 31, 2015
6:30 – 10 p.m.
Fairmont Château Frontenac

Reception: 6:30 p.m.
Banquet, Program and Awards: 7 p.m.

On Halloween, join us and Quebec’s Historic Characters as Ghosts! You may be familiar with Quebec’s historic characters, such as Cartier, Champlain, Frontenac, Wolff, Montcalm and many others. You will have the chance to meet these very important characters who left their marks on Quebec’s history! Each character will present a short, animated and humorous presentation about their roles in Quebec’s history. These “ghosts” will be back to haunt the castle and give the shivers to everyone for just one night!

Dress: Semi-formal attire

Cost: One complimentary ticket will be included with meeting registration (Residents receive two tickets). Additional tickets are $75 USD and can be purchased at the Registration Desk.

FUN NIGHT AT PARLIAMENT

FRIDAY, OCTOBER 30, 2015
7 – 10 p.m.

The Parliament Building is one of the key works of Eugène-Étienne Taché (1836-1912). The quadrilateral building surrounding an inner courtyard was constructed between 1877 and 1886 in the Second Empire style and is unique in North America. Although Taché drew his architectural inspiration from the Louvre in Paris, he also set out to design a building that would tell the story of Quebec.

The imposing fountain at the main entrance pays homage to the Amerindians, Quebec’s first inhabitants. Here too is a pair of remarkable sculptures by Louis-Philippe Hébert—Fisherman with Spear and A Halt in the Forest. The statues decorating the main facade of the Parliament Building represent men and women who shaped the history of Quebec, from the discovery of Canada by Jacques Cartier in 1534 to the birth of Confederation in 1867. Together, these historical figures give meaning to Quebec’s motto, “Je me souviens” (I remember), which Taché had engraved over the main entrance.

Our Fun Night evening will include a tour of the beautiful and breathtaking building. Dinner will be served, and entertainment will be provided by the famous Patrice Painchaud Trio.

For several years now, the Painchaud Family, and particularly Patrice, has been offering various shows promoting international and Quebeoise music. For your evening, Patrice will be joined by two other musicians to form an exceptional trio with an unlimited repertoire. Not only will Patrice amaze you with his musical skills, but you will be charmed by his sense of humor. Beware, his laugh is highly contagious! By the end of the evening, you will want to get up on your feet and even join Patrice! This is truly a breathtaking and interactive evening!

Cost: One complimentary ticket will be included with meeting registration; additional tickets can be purchased for $100 USD for adults and $50 USD for children between the ages of 3 and 18. Children 2 years and under are free. (Please be sure to list the total number of tickets you will need, including yourself, on the registration form.)

Dress: Casual

Transportation to the event will be provided.

Cost:

One complimentary ticket will be included with meeting registration; additional tickets can be purchased for $100 USD for adults and $50 USD for children between the ages of 3 and 18. Children 2 years and under are free. (Please be sure to list the total number of tickets you will need, including yourself, on the registration form.)

Dress: Casual

Transportation to the event will be provided.

Cost:

One complimentary ticket will be included with meeting registration; additional tickets can be purchased for $100 USD for adults and $50 USD for children between the ages of 3 and 18. Children 2 years and under are free. (Please be sure to list the total number of tickets you will need, including yourself, on the registration form.)

Dress: Casual

Transportation to the event will be provided.

Cost:

One complimentary ticket will be included with meeting registration; additional tickets can be purchased for $100 USD for adults and $50 USD for children between the ages of 3 and 18. Children 2 years and under are free. (Please be sure to list the total number of tickets you will need, including yourself, on the registration form.)

Dress: Casual

Transportation to the event will be provided.

Cost:
EXHIBITOR DIRECTORY

COLOR-CODED BADGE KEY
Color-coded badge ribbons will help colleagues and exhibitors quickly identify your specialty.

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Color</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrology</td>
<td>Orange</td>
</tr>
<tr>
<td>Endourology</td>
<td>Purple</td>
</tr>
<tr>
<td>Functional Urology</td>
<td>Teal</td>
</tr>
<tr>
<td>General Urology</td>
<td>Green</td>
</tr>
<tr>
<td>Minimally Invasive Surgery</td>
<td>Turquoise</td>
</tr>
<tr>
<td>Oncology</td>
<td>Light Blue</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>Pink</td>
</tr>
</tbody>
</table>

AbbVie Inc. .................. Booth #: 9
1 North Waukegan Road
North Chicago, IL 60064
Phone: 847-932-7900
Website: www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Allergan, Inc. ................. Booth #: 2
2525 Dupont Drive
Irvine, CA 92612
Phone: 714-246-4500
Website: www.allergan.com

Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world. The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland. For more information, visit www.Allergan.com.

American Medical Systems (AMS) .......... Booth #: 34
10700 Bren Road West
Minnetonka, MN 55343

Astellas Pharma Inc. ......... Booth #: 36,37
1 Astellas Way
Northbrook, IL 60062
Phone: 800-888-7704
Website: www.astellas.com/ena

Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to being a global category leader in Oncology and Urology, and has several oncology compounds in development in addition to enzalutamide. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en.

Astellas Pharma US, Inc. .......... Booth #: 35
1 Astellas Way
Northbrook, IL 60062
Phone: 800-888-7704
Website: www.astellas.us

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving health around the world through innovative and reliable pharmaceutical products. In the US, Astellas focuses on the following therapeutic areas – Cardiology, Infectious Disease, Oncology, Transplant, and Urology.

Boston Scientific ............... Booth #: 24
300 Boston Scientific Way
Marlborough, MA 01752-1234
Website: www.bostonscientific.com

At Boston Scientific, we help you meet the challenges of constant change by delivering innovations across five urology subspecialties, including kidney stones, BPH, erectile dysfunction, male incontinence and pelvic floor disorders. Together, we can advance patient outcomes, reduce procedure costs and enhance quality. Join us as we evolve the future of urology.

Canadian Urological Association ... Booth #: 18
185 Dorval Avenue, Suite 401
Dorval, QC H9S 5J9
Website: www.cua.org

CUA Vision:
The CUA exists to promote the highest standard of urologic care for Canadians and to advance the science of urology

CUA Mission:
The CUA is a national member-based organization dedicated to enabling the profession to provide the highest possible standards of urologic care by collaboratively:

• Fostering excellence in urologic practice through advocacy, education, research and practice support tools
• Leading evidence-based clinical practice through the development of practice standards and guidelines
• Providing continuous professional development for Canadian urologists along the career-path continuum
• Providing leadership in public education for urologic conditions
• Representing the Canadian urologic community in relationships with governments as well as national and international medical societies.

Cogentix Medical ......................... Booth #: 20
40 Ramland Road South
Orangeburg, NY 10962

Coloplast Corp............................. Booth #: 21
1601 West River Road
Minneapolis, MN 55411
Phone: 1-800-258-3476
Email: usmedweb@coloplast.com
Website: www.coloplast.us
Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions to include stress urinary incontinence, pelvic organ prolapse, Peyronie’s disease, kidney stones and ED. Products include the new Titan Touch, Restorelle, Altis, and ReTrace.

Cook Medical............................. Booth #: 4
750 Daniels Way, PO Box 489
Bloomington, IN 47702
Phone: 800-457-4500
Email: Sales.ops@cookmedical.com
Website: www.cookmedical.com
At Cook Medical, patients come first. For over 35 years, we’ve been working to advance urology procedures and improve outcomes, and we’re leading the way with our stone management solutions. We value our quality and won’t compromise it even if it means taking the extra time to make products you and your patients can trust.

Dornier MedTech ......................... Booth #: 25
1155 Roberts Blvd
Kennesaw, GA 30144

EDAP TMS S.A. ......................... Booth #: 33
2201 Denton Drive, Suite 110
Austin, TX 78758

Ferring Pharmaceuticals ................ Booth #: 27
200 Yorkland Blvd., Suite 500
Toronto, Ontario M2J 5C1
Phone: 416-490-0121
Email: ifc@ferring.com
Website: www.ferring.ca
Ferring Pharmaceuticals is a research-driven biopharmaceutical company dedicated to researching, developing and marketing innovative treatments in a number of key therapeutic areas including reproductive health, urology, and gastroenterology. Come visit us to learn more about Firmagon and Nocdurna.

Focal Healthcare Inc. ..................... Booth #: 1
10 Morrow Avenue, Unit 101
Toronto, ON, Canada M6R 2J1
Phone: 647-479-9603
Email: info@focalhealthcare.com
Website: www.focalhealthcare.com
Focal Healthcare has developed an MRI/Ultrasound Fusion biopsy device for improved diagnosis of prostate cancer. Research has proven that the fusion biopsy procedure significantly improves diagnostic accuracy, enabling confident decision-making and better patient care. With an emphasis on accuracy, efficiency and affordability, Focal Healthcare’s Fusion Bx can be integrated into all urology practices.

Genomic Health, Inc. ................. Booth #: 5,6
301 Penobscot Drive
Redwood City, CA 94063
The Oncotype DX® Prostate Cancer Assay is a biopsy-based gene expression test that predicts the biologic aggressiveness of disease in men with clinically low-risk prostate cancer. The Oncotype DX test refines risk stratification, providing critical information for urologists and patients to confidently choose Active Surveillance or immediate treatment.

Hitachi Aloka Medical ..................... Booth #: 10
10 Fairfield Boulevard
Wallingford, CT 06492
Phone: (203) 269-5088
Toll Free: (800) 872-5652
Fax: (203) 269-6075
Email: inquiry@hitachi-aloka.com
Website: www.hitachi-aloka.com
Hitachi Aloka Medical’s commitment to ultrasound in urology offers a wide range of consoles and specifically designed transducers to meet the needs of every doctor. Recognized for our superior image quality, system reliability and use of cutting edge technology, we remain the standard in the field of ultrasound.

Imprimis Pharmaceuticals, Inc. ........ Booth #: 32
12264 El Camino Real, Suite 350
San Diego, CA 92130
Phone: 858-704-4045
Email: esoto@imprimispharma.com or cwhite@imprimispharma.com
Website: www.imprimispharma.com
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary urology formulations including Hep-Lido-A, a patented compounded formulation to address patients suffering from interstitial cystitis, and Trimix-L, a lyophilized compounded formulation for patients suffering from erectile dysfunction.

Janssen Canada booth #: 11
19 Greenbelt Drive
Toronto, Ontario MC3 1L9

KARL STORZ Endoscopy-America, Inc. booth #: 31
2151 E. Grand Avenue
El Segundo, CA 90245
Phone: 424-218-8304
Email: Alisha.vega@karlstorz.com
Website: karlstorz.com
KARL STORZ Endoscopy-America and KARL STORZ Lithotripsy-America are leaders in their respective areas, including endoscopy equipment and shockwave lithotripsy systems. Products range from our FLEX-XC digital flexible video ureterorenoscope that revolutionizes diagnosis and treatment of the upper urinary tract, to the Modulith series of extracorporeal lithotripters for noninvasive stone fragmentation.

Koelis booth #: 30
185 Alewife Brook Parkway,
Cambridge #410MA 02138
Phone: +1 (617) 543-6676
Email: info@koelis.com
Website: www.koelis.com
KOELIS strives to help urologists and radiologists involved in prostate cancer management by designing exclusive interventional planning software based on patented image fusion and Organ-Based Tracking technology. Koelis technology is provided within an easy to use surgical platform that utilizes fully 3D ultrasound images. Well integrated into typical clinical routine, our platforms facilitates planning, guiding, targeting, and recording in the realm of prostate biopsy exams.

Lumenis, Inc. booth #: 3
2033 Gateway Place, Suite 200
San Jose, CA 95110

Maximum Medical Solutions booth #: 13,14
1268 Gambel Oaks Drive
Elizabeth, CO 80107
Phone: 303-725-5614
Email: wendy.poage@maximummedicalsolutions.com
Website: www.maximummedicalsolutions.com

The ability to survive and thrive in the new health care environment is critical. Maximum Medical Solutions provides services to each of the key components of the health care industry including patients, physicians and industry.

Medivation, Inc. booth #: 36,37
525 Market Street, 36th Floor
San Francisco, CA 94105
Phone: 415-543-3470
Website: www.medivation.com
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com.

Memorial Healthcare System booth #: 15
4320 Sheridan Street
Hollywood, FL 33021
Email: MHSDoctor@mhs.net
Phone: 954.265.0900
Website: www.mhs.net & www.memorialphysician.com
Memorial Healthcare System is the third-largest public healthcare system in the United States. A national leader in quality care and patient satisfaction, Memorial has ranked 11 times since 2008 on nationally recognized lists of great places to work – in Modern Healthcare magazine, Florida Trend magazine and Becker’s Hospital Review, just to name a few.
Memorial’s facilities include its flagship, Memorial Regional Hospital, one of the largest in Florida; Memorial Regional Hospital South; Joe DiMaggio Children’s Hospital, the only freestanding children’s hospital in Broward and Palm Beach counties; Memorial Hospital West; Memorial Hospital Miramar; Memorial Hospital Pembroke; and Memorial Manor, a US News five-star-rated nursing home.
Memorial’s work environment has been rated by employees and physicians alike as an open-door, inclusive culture that is committed to safety, transparency and, above all, outstanding service to patients and families.

MIM Software Inc. booth #: 19
25800 Science Park Drvie, Suite 180
Cleveland, OH 44122
Phone: 216-455-0600
Email: bcarruthers@mimsoftware.com
Website: www.mimsoftware.com
MIM Software offers MIM Symphony, a collaborative suite for MR/US fusion prostate biopsy and therapy guidance. State of the art quantitative and qualitative diagnostic radiology tools and a novel, extremely efficient fusion method comprise a complete pathway solution bringing urology and radiology together for the best in prostate cancer diagnostics.
Myriad Gentic Laboratories, Inc. ......... Booth #: 7
320 Wakara Way
Salt Lake City, UT 84108

Olympus America Inc. ......................... 29
3500 Corporate Parkway
Center Valley, PA  18034
Phone: 1-484-896-5000
Website: www.olympusamerica.com

Olympus delivers the highest quality imaging technologies and most advanced energy platforms in the world to enable Urologists to provide treatment options that promote better clinical outcomes. Our integrated technology solutions simplify workflow for clinical staff. We are committed to providing clinical support, professional education, and knowledgeable local account management.

Pacific Edge Diagnostics ......... Booth #: 23
1214 Research Blvd, Suite 2000
Hummelstown, PA 17036

Pendopharm, A Division of Pharmascience, Inc. ................. Booth #: 12
6111 Ave Royalmount
Montreal, Quebec H4P 2T4
Email: aannell@pendopharm.com
Phone: 514-340-9800 ext 3198
Website: www.pendopharm.com

PENDOPHARM is a rapidly growing, independent business that focuses on commercializing a portfolio of specialty prescription products and an established line of OTC/BTC products.

Strategically committed to growth, PENDOPHARM is actively engaged in licensing, developing and marketing late-stage prescription products as well as consumer brands.

Richard Wolf Medical Instruments .... Booth #: 28
353 Corporate Woods Parkway
Vernon Hills, IL 60061
Phone: 800.323.WOLF (9653)
Website: www.richardwolfusa.com

We are a global business with headquarters in Germany and over a century of tradition and expertise in the field of endoscopy. We develop, manufacture and market specific system solutions for minimally invasive human medicine.

Sanofi Canada, Inc. ................. Booth #: 8
2905 Place Louis-R.-Renaud
Laval (Québec) H7V 0A3
Phone: 514 331-9220, 1 800-363-6364
Website: www.sanofi.ca

At Sanofi Oncology, the patient is our inspiration. We are dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients.

Through our global organization of talented and passionate employees, we are building a renewed and diversified portfolio, driven by the principles of innovation, personalization and patient access to medicines.

We believe that delivering innovative treatment solutions requires collaboration with external experts, which is why we partner our own internal expertise with the best experts in scientific discovery and clinical research around the world.

Tolmar Pharmaceuticals .... Booth #: 22
475 Half Day Road
Lincolnshire, IL 60069
Fight Bladder Cancer in a New Light

Studies* have shown that Narrow Band Imaging (NBI®) visualized

- 17% additional patients with Non-Muscle-Invasive Bladder Cancer (NMIBC)
- 24% additional tumors
- 28% additional Carcinoma in Situ (CIS)

* Based on a weighted average.

NBI is not intended to replace histopathological sampling as a means of diagnosis.

Enables visualization of lesion boundaries in NMIBC patients without the need for dyes or drugs. It comes standard with Olympus cystoscopes and camera heads.

For more information on how Olympus video cystoscopes and camera heads with NBI technology and our comprehensive platform of advanced energy devices can improve bladder cancer patient treatment, contact your Olympus Sales Representative or call 800-848-9024.
BIOMARKERS AND GENOMIC TESTING IN PROSTATE CANCER: Integration Into Clinical Practice

FRIDAY, OCTOBER 30, 2015 • 6:45 AM
SALON ROSE
Northeastern Section American Urological Association 2015
Quebec City, Quebec
Fairmont Le Chateau Frontenac

Presenter:
E. David Crawford, MD
Professor of Urology/Surgery/
Radiation Oncology
University of Colorado, Denver
Aurora, Colorado

- Review advances in biomarker development
- Examine the clinical validation of prostate cancer (PCa) biomarkers
- Examine the clinical utility of these biomarkers and how to integrate into practice
- Utilize a case-based approach to demonstrate the clinical utility of new biomarkers
Designed to enhance patient care by helping to:

- Reduce potential administration errors through process automation
- Enable patients to get the right dose at the right time
- Ensure sufficient inventory is on hand using automatic reordering

“I can point to several instances where LuproLink revealed injections that were missed in the paper report. After one year of using LuproLink, the ten office clinical practice has improved patient care, increased its efficiency and eliminated paper record keeping.” – Michael Burnett, COO, Kansas City Urology Care

Please stop by the AbbVie booth for a live demonstration of LuproLink.
Join us

You are cordially invited to attend a hosted lunch and promotional program that will present important information about XTANDI.

Featuring

Liam Hurley, MD, FACS
Northeast Urologic Surgery, P.C.
North Andover, MA

When

Thursday, October 29, from 12:00 PM to 1:00 PM

Where

Salon Rose—Fairmont Le Chateau Frontenac
Quebec, Canada

For all attendees who receive any portion of the meal provided at this program, Astellas Pharma US, Inc. (“Astellas”) and/or Medivation, Inc. (“Medivation”) will report the attendee’s name and the value of the meal received as required by federal and state law. Astellas Pharma US, Inc. and Medivation, Inc. offer you the option to attend the event but not receive the meal. Please ask the Program Organizer for more information about this opt-out option.

In addition, if you are licensed in Vermont or Minnesota, or affiliated with the US Department of Veterans Affairs or Department of Defense, you may be prohibited from accepting the meal sponsored by Astellas and Medivation at this program. You are responsible for understanding and complying with any such restrictions. Please inform the Program Organizer if you are licensed in any of the aforementioned states. You may also avail yourself of the opt-out option to attend the event but not receive the meal. Please ask the Program Organizer for more information about the opt-out option.

Astellas and Medivation have adopted the PhRMA Code on Interactions with Healthcare Professionals. For this reason, we cannot pay for the expenses of a healthcare professional’s spouse or guest, nor can they attend meals. We appreciate your understanding and support of our commitment to these ethical standards.

Visit XtandiHCP.com
Making a difference means taking the lead.

As leaders in Urology, we make it our priority to stay on the cutting edge of urologic research to address unmet needs in Urology. Our commitment extends beyond product development. We seek to establish meaningful collaborations and alliances throughout the Urology community.

Changing the Urology of tomorrow, today.
COMPREHENSIVE PELVIC HEALTH SOLUTIONS

• Equipment
• Disposables
• Service
• Education

Goby™
Wireless Urodynamics and Anorectal Manometry

Urostym®
Pelvic Floor Rehabilitation for Adults and Children

Urocap™ IV Light Flowmeter
Bluetooth® Connection to Android Tablet

injeTAK® Cystoscopy Needle
Adjustable Depth for Precise Injections

Visit our website at www.laborie.com
or contact your local sales rep
Save the Date

BUFFALO NEW YORK

68TH NSAUA ANNUAL MEETING
SEPTEMBER 29 – OCTOBER 1, 2016